US20190046690A9 - Materials with improved properties - Google Patents
Materials with improved properties Download PDFInfo
- Publication number
- US20190046690A9 US20190046690A9 US15/341,118 US201615341118A US2019046690A9 US 20190046690 A9 US20190046690 A9 US 20190046690A9 US 201615341118 A US201615341118 A US 201615341118A US 2019046690 A9 US2019046690 A9 US 2019046690A9
- Authority
- US
- United States
- Prior art keywords
- substituted
- independently
- integer
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000463 material Substances 0.000 title abstract description 40
- 230000001976 improved effect Effects 0.000 title abstract description 11
- 238000002513 implantation Methods 0.000 claims abstract description 10
- -1 polydimethylsiloxane Polymers 0.000 claims description 303
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 294
- 229910052739 hydrogen Inorganic materials 0.000 claims description 286
- 239000001257 hydrogen Substances 0.000 claims description 285
- 125000003545 alkoxy group Chemical group 0.000 claims description 210
- 125000000217 alkyl group Chemical group 0.000 claims description 195
- 125000003342 alkenyl group Chemical group 0.000 claims description 191
- 125000004414 alkyl thio group Chemical group 0.000 claims description 190
- 125000000304 alkynyl group Chemical group 0.000 claims description 190
- 229910052799 carbon Inorganic materials 0.000 claims description 178
- 125000003282 alkyl amino group Chemical group 0.000 claims description 173
- 125000000623 heterocyclic group Chemical group 0.000 claims description 162
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 155
- 125000003368 amide group Chemical group 0.000 claims description 152
- 229910052760 oxygen Inorganic materials 0.000 claims description 146
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 143
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 136
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 135
- 125000005499 phosphonyl group Chemical group 0.000 claims description 129
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 119
- 125000001072 heteroaryl group Chemical group 0.000 claims description 115
- 229910052757 nitrogen Inorganic materials 0.000 claims description 109
- 229910052717 sulfur Inorganic materials 0.000 claims description 106
- 125000003118 aryl group Chemical group 0.000 claims description 105
- 210000004027 cell Anatomy 0.000 claims description 95
- 239000001301 oxygen Substances 0.000 claims description 74
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 72
- 239000011593 sulfur Chemical group 0.000 claims description 60
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 58
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 52
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 45
- 238000007385 chemical modification Methods 0.000 claims description 37
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 35
- 229910020008 S(O) Inorganic materials 0.000 claims description 33
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 31
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 125000003107 substituted aryl group Chemical group 0.000 claims description 30
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 28
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 26
- 239000007943 implant Substances 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 125000005110 aryl thio group Chemical group 0.000 claims description 16
- 108090000765 processed proteins & peptides Chemical group 0.000 claims description 15
- 102000004877 Insulin Human genes 0.000 claims description 14
- 108090001061 Insulin Proteins 0.000 claims description 14
- 229940125396 insulin Drugs 0.000 claims description 14
- HDCXQTPVTAIPNZ-UHFFFAOYSA-N n-({[4-(aminosulfonyl)phenyl]amino}carbonyl)-4-methylbenzenesulfonamide Chemical group C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NC1=CC=C(S(N)(=O)=O)C=C1 HDCXQTPVTAIPNZ-UHFFFAOYSA-N 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 8
- 229920001184 polypeptide Chemical group 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 150000001413 amino acids Chemical group 0.000 claims description 7
- 239000011148 porous material Substances 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 239000012510 hollow fiber Substances 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 229920002492 poly(sulfone) Polymers 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 229920000570 polyether Polymers 0.000 claims 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims 1
- 239000004810 polytetrafluoroethylene Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 abstract description 47
- 230000004048 modification Effects 0.000 abstract description 47
- 230000004044 response Effects 0.000 abstract description 24
- 230000009286 beneficial effect Effects 0.000 abstract description 7
- 206010070245 Foreign body Diseases 0.000 abstract description 4
- 125000001424 substituent group Chemical group 0.000 description 237
- 239000000047 product Substances 0.000 description 225
- 125000004432 carbon atom Chemical group C* 0.000 description 209
- 125000002947 alkylene group Chemical group 0.000 description 159
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 136
- 150000003462 sulfoxides Chemical class 0.000 description 129
- 150000001875 compounds Chemical class 0.000 description 103
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 87
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 64
- 150000001721 carbon Chemical group 0.000 description 63
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 61
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 60
- 229910052701 rubidium Inorganic materials 0.000 description 54
- 125000000753 cycloalkyl group Chemical group 0.000 description 50
- 125000004122 cyclic group Chemical group 0.000 description 49
- 229910019142 PO4 Inorganic materials 0.000 description 46
- 125000005842 heteroatom Chemical group 0.000 description 46
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 46
- 239000010452 phosphate Substances 0.000 description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- 125000002837 carbocyclic group Chemical group 0.000 description 40
- 125000002877 alkyl aryl group Chemical group 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 150000003573 thiols Chemical class 0.000 description 29
- 125000004043 oxo group Chemical group O=* 0.000 description 27
- 125000004093 cyano group Chemical group *C#N 0.000 description 24
- 229910052736 halogen Inorganic materials 0.000 description 22
- 150000002367 halogens Chemical class 0.000 description 22
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 21
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 21
- 150000002148 esters Chemical class 0.000 description 20
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 20
- 150000001540 azides Chemical class 0.000 description 19
- 238000000576 coating method Methods 0.000 description 19
- 125000001188 haloalkyl group Chemical group 0.000 description 19
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 19
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 19
- 150000007970 thio esters Chemical class 0.000 description 19
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 19
- 125000002252 acyl group Chemical group 0.000 description 18
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 18
- 150000001409 amidines Chemical class 0.000 description 18
- 239000011248 coating agent Substances 0.000 description 18
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 18
- 150000002466 imines Chemical class 0.000 description 18
- AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 18
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 18
- 239000002775 capsule Substances 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 15
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 15
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 description 15
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 125000000392 cycloalkenyl group Chemical group 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 239000012620 biological material Substances 0.000 description 12
- 229940088597 hormone Drugs 0.000 description 12
- 239000005556 hormone Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 230000001575 pathological effect Effects 0.000 description 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 10
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 10
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 10
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 7
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 6
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 210000003890 endocrine cell Anatomy 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 210000004153 islets of langerhan Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000013626 chemical specie Substances 0.000 description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 125000000962 organic group Chemical group 0.000 description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 150000003456 sulfonamides Chemical class 0.000 description 4
- 125000000542 sulfonic acid group Chemical group 0.000 description 4
- 125000003375 sulfoxide group Chemical group 0.000 description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 230000003510 anti-fibrotic effect Effects 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 150000003949 imides Chemical class 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 2
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 2
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 2
- 125000005986 4-piperidonyl group Chemical group 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- VPUGDVKSAQVFFS-UHFFFAOYSA-N coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000004928 piperidonyl group Chemical group 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000005512 benztetrazolyl group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000004703 blastocyst inner cell mass Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- VXRUJZQPKRBJKH-UHFFFAOYSA-N corannulene Chemical compound C1=CC(C2=C34)=CC=C3C=CC3=C4C4=C2C1=CC=C4C=C3 VXRUJZQPKRBJKH-UHFFFAOYSA-N 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000004932 phenoxathinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000003566 thiocarboxylic acids Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/10—Ceramics or glasses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/12—Chemical modification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
- A61F2002/009—Special surfaces of prostheses, e.g. for improving ingrowth for hindering or preventing attachment of biological tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
Definitions
- This invention is in the field of materials with improved properties, e.g., biocompatibility, particularly implantable devices with reduced foreign body response and moieties that confer improved properties, e.g., biocompatibility.
- the foreign body response is an immune-mediated reaction that impacts the fidelity of implanted biomedical devices (Anderson et al., Semin. Immunol. 20:86-100 (2008); Langer, Adv. Mater. 21:3235-3236 (2009); Ward, J. Diabetes Sci. Technol. Online 2:768-777 (2008); Harding & Reynolds, Trends Biotechnol. 32:140-146 (2014)). Macrophage recognition of biomaterial surfaces in these devices initiate a cascade of inflammatory events that result in the fibrous and collagenous encapsulation of these foreign materials (Anderson et al. (2008); Ward (2008); Harding & Reynolds (2014); Grainger, Nat. Biotechnol.
- the foreign body response to implanted biomaterials is the culmination of inflammatory events and wound-healing processes resulting in implant encapsulation (Anderson et al. (2008)).
- the final pathological product of this response is fibrosis, which is characterized by the accumulation of excessive extracellular matrix at sites of inflammation and is a key obstacle for implantable medical devices as the cellular and collagenous deposition isolate the device from the host (Anderson et al. (2008); Wick et al., Annu. Rev. Immunol. 31:107-135 (2013); Wynn & Ramalingam, Nat. Med. 18:1028-1040 (2012)).
- This device isolation can interfere with sensing of the host environment, lead to painful tissue distortion, cut off nourishment (for implants containing living, cellular components), and ultimately lead to device failure.
- Materials commonly used for medical device manufacture today elicit a foreign body response that results in fibrous encapsulation of the implanted material (Langer (2009); Ward (2008); Harding & Reynolds (2014); Williams (2008); Zhang et al., Nat. Biotechnol. 31:553-556 (2013)).
- Overcoming the foreign body response to implanted devices could pave the way for implementing new medical advances, making the development of materials with both anti-inflammatory and anti-fibrotic properties a critical medical need (Anderson et al. (2008); Langer (2009); Harding & Reynolds (2014)).
- Macrophages are a key component of material recognition and actively adhere to the surface of foreign objects (Anderson et al. (2008); Ward (2008); Grainger, Nat. Biotechnol. 31:507-509 (2013); Sussman et al., Ann. Biomed. Eng. 1-9 (2013) (doi:10.1007/s10439-013-0933-0)).
- Objects too large for macrophage phagocytosis initiate processes that result in the fusion of macrophages into foreign-body giant cells.
- These multi-nucleated bodies amplify the immune response by secreting cytokines and chemokines that result in the recruitment of fibroblasts that actively deposit matrix to isolate the foreign material (Anderson et al.
- Products such as devices, prostheses, and materials, having surfaces comprising moieties or compounds that impart beneficial properties to these products are disclosed.
- the surface-modified products have optimized properties, e.g., improved biocompatibility, compared to a corresponding product that lacks the moieties or compounds on its surface.
- the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
- the surfaces of the products can be covalently modified using chemical compounds.
- the chemical compounds contain hydrophobic groups.
- the chemical compounds contain aryl/heteroaryl groups.
- the chemical compounds contain a triazole linked to a moiety or compound that can provide anti-fibrotic properties.
- the moiety can be tetrahydropyran, thiomorpholine-1,1-dioxide, or aniline.
- the products described herein can be implanted or administered to a subject comprising a human or an animal including, but not limited to, a mouse, dog, cat, horse, bovine or ovine and the like, that is in need thereof, e.g., in need of alleviation or amelioration from a disorder, e.g., a recognized medical condition.
- a subject comprising a human or an animal including, but not limited to, a mouse, dog, cat, horse, bovine or ovine and the like, that is in need thereof, e.g., in need of alleviation or amelioration from a disorder, e.g., a recognized medical condition.
- the product can be formed from a starting material or intermediate which includes the moiety or compound.
- the product can be formed by covalently modifying a starting material or the surface of a starting material, intermediate, or an otherwise finished object.
- the surface or a surface of the product can be chemically modified after formation of the product with one or more compounds.
- the compounds are preferably compounds that confer a beneficial effect, such as lower foreign body response and improved biocompatibility, on the product.
- the modifying compounds can provide anti-fibrotic properties. Also disclosed are methods of chemically modifying products and methods of using the chemically modified products, such as by implantation into a subject.
- the compound can have a structure —X—R 1 , where
- X is oxygen, sulfur, NR 2 , or another group compatible with attachment or coupling of the compound to a product or surface;
- R 1 is hydrogen, or an organic grouping containing any number of carbon atoms, preferably 1-30 carbon atoms, more preferably 1-20 carbon atoms, more preferably 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R 1 organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 2 +Q 3 ); and
- R 2 is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R 2 organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 3 ).
- R 1 is, independently in one or more sites of chemical modification
- A is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 3 );
- B, and C are, independently, absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 3 ); and
- ⁇ is an integer from, as valency permits, 0 to 30.
- R 1 is, independently in one or more sites of chemical modification
- R 3 is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R 3 organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 3 ); and
- R b is absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R b organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 3 ).
- a and R 3 can be, independently, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 3 ).
- B, C, and R b can be, independently, absent, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 3 ).
- a and R 3 can be, independently, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J 1 .
- a and R 3 can be, independently, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J 2 .
- B, C, and R b independently in combination with any embodiments of any other relevant substituent classes, B, C, and R b can be, independently, absent, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J 1 .
- B, C, and R b independently in combination with any embodiments of any other relevant substituent classes, B, C, and R b can be, independently, absent, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J 2 .
- a and R 3 can be, independently,
- z is an integer from 0-11; wherein w is an integer from 0-9; wherein k is an integer from 0 to 20;
- R d are independently B, C, —B(—C) ⁇ , R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- X d are independently absent, O, or S;
- R c is B, C, —B(—C) ⁇ , R b , absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 3 );
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently B, C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently B, C, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- z is an integer from 0-11; wherein w is an integer from 0-9; wherein k is an integer from 0 to 20;
- R d are independently C, R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- X d are independently absent, O, or S;
- R c is C, R b , absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 );
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, R b , absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- z is an integer from 0-11; wherein w is an integer from 0-9; wherein k is an integer from 0 to 20;
- R d are independently C, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- X d are independently absent, O, or S;
- R c is C, absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 );
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- z is an integer from 0-11; wherein w is an integer from 0-9; wherein k is an integer from 0 to 20;
- R d are independently U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- X d are independently absent, O, or S;
- R c is absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 );
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- a and R 3 can be, independently,
- z is an integer from 0-11; wherein w is an integer from 0-9;
- R d are independently B, C, —B(—C) ⁇ , R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently B, C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- z is an integer from 0-11; wherein w is an integer from 0-9;
- R d are independently C, R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, R b , absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- z is an integer from 0-11; wherein w is an integer from 0-9;
- R d are independently C, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- z is an integer from 0-11; wherein w is an integer from 0-9;
- R d are independently U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- a and R 3 can be, independently,
- z is an integer from 0-11;
- R d are independently B, C, —B(—C) ⁇ , R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently B, C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- z is an integer from 0-11;
- R d are independently C, R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, R b , absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- z is an integer from 0-11;
- R d are independently C, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- z is an integer from 0-11;
- R d are independently U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- a and R 3 can be, independently,
- w is an integer from 0-9;
- R d are independently B, C, —B(—C) ⁇ , R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently B, C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- w is an integer from 0-9;
- R d are independently C, R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, R b , absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- w is an integer from 0-9;
- R d are independently C, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- w is an integer from 0-9;
- R d are independently U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- a and R 3 can be, independently,
- w is an integer from 0-9;
- R d are independently B, C, —B(—C) ⁇ , R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, wherein one, two, three, or four of R 12 , R 13 , R 14 , R 15 , and R 16 are N and the others are C, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently B, C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- w is an integer from 0-9;
- R d are independently C, R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, wherein one, two, three, or four of R 12 , R 13 , R 14 , R 15 , and R 16 are N and the others are C, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, R b , absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- w is an integer from 0-9;
- R d are independently C, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, wherein one, two, three, or four of R 12 , R 13 , R 14 , R 15 , and R 16 are N and the others are C, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- w is an integer from 0-9;
- R d are independently U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, wherein one, two, three, or four of R 12 , R 13 , R 14 , R 15 , and R 16 are N and the others are C, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- a and R 3 can be, independently,
- k is an integer from 0 to 20;
- X d are independently absent, O, or S;
- R c is B, C, —B(—C) ⁇ , R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently B, C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- k is an integer from 0 to 20;
- X d are independently absent, O, or S;
- R c is C, R b , absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- k is an integer from 0 to 20;
- X d are independently absent, O, or S;
- R c is C, absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- k is an integer from 0 to 20;
- X d are independently absent, O, or S;
- R c is absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- a and R 3 can be, independently,
- k is an integer from 0 to 20;
- X d are independently O or S;
- R c is B, C, —B(—C) ⁇ , R b , absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently B, C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- k is an integer from 0 to 20;
- X d are independently O or S;
- R c is C, R b , absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- k is an integer from 0 to 20;
- X d are independently O or S;
- R c is C, absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- k is an integer from 0 to 20;
- X d are independently O or S;
- R c is absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- a and R 3 can be, independently,
- k is an integer from 1 to 20;
- R c is B, C, —B(—C) ⁇ , R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently B, C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- k is an integer from 1 to 20;
- R c is C, R b , absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- k is an integer from 1 to 20;
- R c is C, absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- k is an integer from 1 to 20;
- R c is absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- R 1 is, independently in one or more sites of chemical modification
- R a and R b are independently selected from U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 2 +Q 3 ), and R b is independently selected from U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 3 ,
- R 3 , R 4 , and R 5 are, independently, hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- the compound can have a structure —X—R 1 , where
- X is oxygen, sulfur, NR 2 , or another group compatible with attachment or coupling of the compound to a product or surface;
- R 1 is, independently in one or more sites of chemical modification, hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 );
- R 2 is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R 2 organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- R 1 is, independently in one or more sites of chemical modification
- R a is independently selected from U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 2 +Q 3 ), and R b is independently selected from U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 3 , U 3 +Q
- R 3 , R 4 , and R 5 are, independently, hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R 3 , R 4 , and R 5 organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- a can be an integer from 1 to 30, 2 to 30, 3 to 30, 4 to 30, 5 to 30, 6 to 30, 7 to 30, 8 to 30, 9 to 30, 10 to 30, 11 to 30, 12 to 30, 13 to 30, 14 to 30, 15 to 30, 16 to 30, 17 to 30, 18 to 30, 19 to 30, 20 to 30, 21 to 30, 22 to 30, 23 to 30, 24 to 30, 25 to 30, 26 to 30, 27 to 30, 28 to 30, 29 to 30, 1 to 29, 2 to 29, 3 to 29, 4 to 29, 5 to 29, 6 to 29, 7 to 29, 8 to 29, 9 to 29, 10 to 29, 11 to 29, 12 to 29, 13 to 29, 14 to 29, 15 to 29, 16 to 29, 17 to 29, 18 to 29, 19 to 29, 20 to 29, 21 to 29, 22 to 29, 23 to 29, 24 to 29, 25 to 29, 26 to 29, 27 to 29, 28 to 29, 1 to 29, 26 to 29, 27 to 29, 28 to 29, 1 to 29, 26 to 29, 27 to 29, 28 to 29, 1 to 29, 26 to 29, 27 to 29, 28 to 29, 1 to 29, 26 to 29, 27 to 29, 28 to 29, 1 to 28, 2 to 28, 3 to 28, 4 to 28, 5 to 28, 6 to 28, 7 to 28, 8 to 28, 9 to 28, 10
- a can be an integer from 1 to 10, 2 to 10, 3 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10, 9 to 10, 1 to 9, 2 to 9, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 1 to 8, 2 to 8, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 1 to 7, 2 to 7, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 1 to 6, 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2.
- a can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- a can be an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. In preferred embodiments, a is 1, 2, 3, 4, or 5.
- m can be an integer from 3 to 16, 4 to 16, 5 to 16, 6 to 16, 7 to 16, 8 to 16, 9 to 16, 10 to 16, 11 to 16, 12 to 16, 13 to 16, 14 to 16, 15 to 16, 3 to 15, 4 to 15, 5 to 15, 6 to 15, 7 to 15, 8 to 15, 9 to 15, 10 to 15, 11 to 15, 12 to 15, 13 to 15, 14 to 15, 3 to 14, 4 to 14, 5 to 14, 6 to 14, 7 to 14, 8 to 14, 9 to 14, 10 to 14, 11 to 14, 12 to 14, 13 to 14, 3 to 13, 4 to 13, 5 to 13, 6 to 13, 7 to 13, 8 to 13, 9 to 13, 10 to 13, 11 to 13, 12 to 13, 3 to 12, 4 to 12, 5 to 12, 6 to 12, 7 to 12, 8 to 12, 9 to 12, 10 to 12, 11 to 12, 3 to 11, 4 to 11, 5 to 11, 6 to 11, 7 to 11, 8 to 11, 9 to 11, 10 to 11, 3 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10, 9 to 10, 3 to 9, 4 to 9, 5 to 9, 6 to 9,
- m can be an integer from 3 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10, 9 to 10, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 3 to 6, 4 to 6, 5 to 6, 3 to 5, 4 to 5, and 3 to 4.
- m can be 3, 4, 5, 6, 7, 8, 9, or 10.
- n can be an integer from 3 to 5, 4 to 5, or 3 to 4. In preferred embodiments, m is 3, 4, or 5.
- n can be an integer from 1 to 12, 2 to 12, 3 to 12, 4 to 12, 5 to 12, 6 to 12, 7 to 12, 8 to 12, 9 to 12, 10 to 12, 11 to 12, 1 to 11, 2 to 11, 3 to 11, 4 to 11, 5 to 11, 6 to 11, 7 to 11, 8 to 11, 9 to 11, 10 to 11, 1 to 10, 2 to 10, 3 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10, 9 to 10, 1 to 9, 2 to 9, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 1 to 8, 2 to 8, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 1 to 7, 2 to 7, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 1 to 6, 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2.
- n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
- n can be an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. In preferred embodiments, n is 1, 2, 3, 4, or 5.
- R 3 is —CH 2 —Ar— or —CH 2 —CH 2 —(O—CH 2 —CH 2 ) 3 —;
- R 2 is hydrogen;
- R 4 is hydrogen, methyl, —COOH, —CH 2 —O—CH 2 —CH 2 —OH, or —CH 2 —OH;
- R 5 is methyl, —COCH 3 , —CH 2 —N(CH 2 —CH 3 ) 2 , —N(CH 2 —CH 3 ) 2 , —CH 2 —O—CH 3 , —(CH 2 ) 6 —CH 3 , —CH 2 —O—CH 2 —CH 2 —OH, —CH 2 —CH(COOH)—(CH 2 ) 5 —CH 3 ,
- R 4 is hydrogen
- R 4 is hydrogen
- R 5 is methyl, —COCH 3 , or —CH 2 —N(CH 2 —CH 3 ) 2 .
- X is oxygen or NR 2 , wherein R 2 is hydrogen, methyl, or —CH 2 —CH 3 ; and R 1 is —CH 2 —CH 2 —CH 2 —CH 2 —OH, —CH 2 —CH 2 —(O—CH 2 —CH 2 ) n —O—CH 3 , where n is an integer from 3 to 16, —CH 2 —CH 2 —O—CH 2 —CH 2 —OH, —(CH 2 —CH 2 ) 3 —NH—CH 3 ,
- X is oxygen, sulfur, or NR 2 , wherein R 2 is hydrogen, alkyl, or substituted alkyl, wherein R 1 is
- R 18 in A is —(CR 19 R 19 ) p —; p is an integer from 0 to 5; each R 19 is hydrogen; each R d is independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic; z is an integer from 0 to 11; R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C or N, wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none,
- R 18 in B is —(CR 19 R 19 ) p —; p is an integer from 0 to 5; each R 19 is hydrogen; each R d is independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic; w is an integer from 0 to 4; each R 12 , R 13 , R 14 , R 15 , and R 16 , are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one
- R 18 in C is —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5;
- X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 ;
- each R 19 is hydrogen;
- R 20 is alkyl or substituted alkyl;
- R d are independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic,
- X is oxygen, sulfur, or NR 2 , wherein R 2 is hydrogen, alkyl, or substituted alkyl,
- R 18 in A is —(CH 2 ) p —; p is an integer from 0 to 5; each R d is independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic; z is an integer from 0 to 11; R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C or N, wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, wherein R 12 to R 17 are bound to none, one, or two hydrogens according to
- R 18 in B is —(CH 2 ) p —; p is an integer from 0 to 5; each R d is independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic; w is an integer from 0 to 4; each R 12 , R 13 , R 14 , R 15 , and R 16 , are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to
- R 18 in C is —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, p is 1 and q is 0; X b is —O—; each R 19 is hydrogen; R d are independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic; z is an integer from 0 to 11; each R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, or S, wherein the
- X is oxygen, sulfur, or NR 2 , wherein R 2 is hydrogen, alkyl, or substituted alkyl,
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 in A are independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, alkoxy, substituted alkoxy, aroxy, substituted aroxy, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, substituted heterocyclic, poly(ethylene glycol), or poly(lactic-co-glycolic acid); k is an integer from 0 to 20; each X d is independently absent, O, or S; and R c is
- R 18 in B is —(CR 19 R 19 ) p —; p is an integer from 0 to 5; each R 19 is hydrogen; each R d is independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic; w is an integer from 0 to 4; each R 12 , R 13 , R 14 , R 15 , and R 16 , are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one
- R 18 in C is —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5;
- X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 ;
- each R 19 is hydrogen;
- R 20 is alkyl or substituted alkyl;
- R d are independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic,
- X is oxygen, sulfur, or NR 2 , wherein R 2 is hydrogen, alkyl, or substituted alkyl,
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 in A are independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, alkoxy, substituted alkoxy, aroxy, substituted aroxy, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, substituted heterocyclic, poly(ethylene glycol), or poly(lactic-co-glycolic acid); k is an integer from 0 to 20; each X d is independently absent, O, or S; and R c is
- R 18 in B is —(CR 19 R 19 ) p —; p is an integer from 0 to 5; each R 19 is hydrogen; each R d is independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic; w is an integer from 0 to 4; each R 12 , R 13 , R 14 , R 15 , and R 16 , are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one
- R 18 in C is —(CR 19 R 19 ) p —; p is an integer from 0 to 5; each R 19 is hydrogen; R d are independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic; z is an integer from 0 to 11; wherein R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, N, or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R
- the compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-N-phenyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the product includes a cargo or payload, such as a biological material.
- a biological material can be cells or tissue.
- the cargo is disposed within an outer member (e.g. a coating or encapsulating layer) that includes compounds as described herein on its surface.
- the product can be a cardiac pacemaker, a catheter, a needle injection catheter, a blood clot filter, a vascular transplant, a balloon, a stent transplant, a biliary stent, an intestinal stent, a bronchial stent, an esophageal stent, a ureteral stent, an aneurysm-filling coil or other coil device, a surgical repair mesh, a transmyocardial revascularization device, a percutaneous myocardial revascularization device, a prosthesis, an organ, a vessel, an aorta, a heart valve, a tube, an organ replacement part, an implant, a fiber, a hollow fiber, a membrane, a textile, banked blood, a blood container, a titer plate, an adsorber media, a dialyzer, a connecting piece, a sensor, a valve, an endoscope, a filter, a pump chamber,
- the product includes cells or tissues encapsulated or coated with a polymer, where the surface or a surface of the polymeric product includes compounds as described herein.
- a polymer such as
- the polymer comprises polydimethylsiloxane (PDMS);
- the compound comprises the formula -A-B(—C) ⁇ (Formula XIII), where A is Formula VIII or Formula VI, B is Formula IX, ⁇ is 1, C is Formula VI;
- the product is spherical or spheroidal in shape
- the cell is a cell producing a recombinant product
- the product has a pore size of 0.1 to 1 ⁇ m.
- the product is provided as a preparation of products and the products in the preparation have one or more of the following characteristics:
- At least 50% of the products in the preparation have a surface with a concentration of 1 to 5% surface modifications as measured by X-ray photoelectron spectroscopy (XPS);
- the product has properties (1) and (2).
- the product has properties (1) and (3).
- the product has properties (1) and (4).
- the product has properties (2) and (3).
- the product has properties (2) and (4).
- the product has properties (3) and (4).
- the product has properties (1), (2), and (3).
- the product has properties (1), (2), (3). and (4).
- At least 5% of the cells are alive after 30 days.
- the cells when implanted into the subject, the cells respond to an increase in blood glucose by secreting insulin.
- the product is singularly modified with the compound of (b).
- the product is encapsulated or coated with a polymer, wherein the polymer comprises a compound with a structure-X—R 1 , wherein X is oxygen, sulfur, NR 2 , or another group compatible with attachment or coupling of the compound to a product or surface; R 2 is hydrogen, alkyl, or substituted alkyl; and R 1 is
- R 18 in A is —(CH 2 ) p —; p is an integer from 0 to 5; each R d is independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic; z is an integer from 0 to 11; R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C or N, wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, wherein R 12 to R 17 are bound to none, one, or two hydrogens according to
- R 18 in B is —(CH 2 ) p —; p is an integer from 0 to 5; each R d is independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic; w is an integer from 0 to 4; each R 12 , R 13 , R 14 , R 15 , and R 16 , are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to
- R 18 in C is —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, p is 1 and q is 0; X b is —O—; each R 19 is hydrogen; R d are independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic; z is an integer from 0 to 11; each R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, or S, wherein the
- ⁇ is 1; and wherein the product has one or more characteristics selected from:
- the product is encapsulated or coated with a polymer, wherein the polymer comprises a compound with a structure-X—R 1 , wherein X is oxygen, sulfur, NR 2 , or another group compatible with attachment or coupling of the compound to a product or surface; R 2 is hydrogen, alkyl, or substituted alkyl; and R 1 is
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 in A are independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, alkoxy, substituted alkoxy, aroxy, substituted aroxy, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, substituted heterocyclic, poly(ethylene glycol), or poly(lactic-co-glycolic acid); k is an integer from 0 to 20; each X d is independently absent, O, or S; and R c is
- R 18 in B is —(CR 19 R 19 ) p —; p is an integer from 0 to 5; each R 19 is hydrogen; each R d is independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic; w is an integer from 0 to 4; each R 12 , R 13 , R 14 , R 15 , and R 16 , are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one
- R 18 in C is —(CR 19 R 19 ) p —; p is an integer from 0 to 5; each R 19 is hydrogen; R d are independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, or substituted heterocyclic; z is an integer from 0 to 11; wherein R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, N, or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R
- ⁇ is 1; and wherein the product has one or more characteristics selected from:
- the product is multiply modified with the compound of (b) and another compound of different structure (for example, another compound as disclosed herein).
- the product is purified after chemical modification to remove any unreacted or partially reacted contaminants present with the chemically modified product, wherein the purified chemically modified product induces a lower foreign body response than a similar product that has not been chemically modified.
- Biocompatible refers to a substance or object that performs its desired function when introduced into an organism without inducing significant inflammatory response, immunogenicity, or cytotoxicity to native cells, tissues, or organs.
- a biocompatible product is a product that performs its desired function when introduced into an organism without inducing significant inflammatory response, immunogenicity, or cytotoxicity to native cells, tissues, or organs.
- Biocompatibility as used herein, can be quantified using the in vivo biocompatibility assay described below.
- a material or product as disclosed can be considered biocompatible if it produces, in a test of biocompatibility related to immune system reaction less than 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 8%, 6%, 5%, 4%, 3%, 2%, or 1% of the reaction, in the same test of biocompatibility, produced by a material or product the same as the test material or product except for a lack of the surface modification on the test material or product.
- useful biocompatibility tests include measuring and assessing cytotoxicity in cell culture, inflammatory response after implantation (such as by fluorescence detection of cathepsin activity), and immune system cells recruited to implant (for example, macrophages and neutrophils).
- Formal body response refers to the immunological response of biological tissue to the presence of any foreign material in the tissue which can include protein adsorption, macrophages, multinucleated foreign body giant cells, fibroblasts, and angiogenesis.
- Contacting refers to any way for coating a product, using one or more of the compounds disclosed herein, on a substrate such as a product. Contacting can include, but is not limited to, intraoperative dip-coating, spraying, wetting, immersing, dipping, painting, bonding or adhering, stepwise surface derivatization, or otherwise providing a substrate or surface with a compound.
- the compound can be covalently attached, non-covalently attached, or both, to the substrate or surface.
- Coating refers to any temporary, semi-permanent or permanent layer, covering or surface.
- a coating can be applied as a gas, vapor, liquid, paste, semi-solid, or solid.
- a coating can be applied as a liquid and solidified into a hard coating.
- Elasticity can be engineered into coatings to accommodate pliability, e.g. swelling or shrinkage, of the substrate or surface to be coated.
- Chemical modification refers to chemical modification of the product. Generally, such chemical modification is by direct attachment, coupling, or adherence of a compound to the surface material of the product. Preferably, the chemical modification involves modification with one or more of the disclosed compounds. Chemical modification, as defined herein in the context of the disclosed products, can be accomplished at any time and in any manner, including, for example, synthesis or production of the modified form of the product or material when the product or material is formed, addition of the chemical modification after the final product or material is formed, or at any time in between.
- addition or application of a material, compound, or composition to a starting material or intermediate before it is made into or incorporated into the final product can be specifically excluded.
- chemical modification of alginate or another polymer prior to the polymer being incorporated into a capsule or other structure can be, in some embodiments, specifically excluded as the manner of producing a chemical modification of the capsule or structure.
- coating a device, prosthesis, or other product with a material that was chemically modified prior to being applied as a coating can be, in some embodiments, specifically excluded as the manner of producing a chemical modification of the device, prosthesis, or product.
- coating of or addition to the product of another material that has chemical modifications does not alter the fact that the product was chemically modified according to the meaning of the term used herein.
- addition or application of a material, compound, or composition to a starting material or intermediate before it is made into or incorporated into the final product can be specifically excluded.
- chemical or surface modification of alginate or another polymer prior to the polymer being incorporated into a capsule or other structure can be, in some embodiments, specifically excluded as the manner of producing a surface modification of the capsule or structure.
- coating a device, prosthesis, or other product with a material that was chemically modified prior to being applied as a coating can be, in some embodiments, specifically excluded as the manner of producing a surface modification of the device, prosthesis, or product.
- coating of or addition to the product of another material that has chemical modifications does not alter the fact that the product was surface modified according to the meaning of the term used herein.
- the moieties or compounds modifying the product can be present on the surface or a surface of the product, and are not present, or are not present in a significant amount, elsewhere in the product, e.g., on internal or interior surfaces. In some embodiments, at least 50, 60, 70, 80, 90, 95, or 99% of the moieties or compounds are present on the surface or a surface of the product. In some embodiments, the moieties or compounds are present on the exterior face of the surface or a surface of the product, and are not present, or not present in a significant amount, elsewhere in the product, e.g., on internal or interior surfaces. In some embodiments, at least 50, 60, 70, 80, 90, 95, or 99% of the moieties or compounds are present on the external face of the surface or a surface of the product.
- the moieties or compounds modifying the product can be present on a portion or component of the product, and are not present, or are not present in a significant amount, elsewhere in the product. Such differences can be referred to as asymmetry of the modification or coating.
- at least 50, 60, 70, 80, 90, 95, or 99% of the moieties or compounds are present on the portion or component of the product.
- the moieties or compounds are present on the exterior face of the portion or component of the product, and are not present, or not present in a significant amount, elsewhere in the product.
- at least 50, 60, 70, 80, 90, 95, or 99% of the moieties or compounds are present on the external face of the portion or component of the product.
- the surface or a surface of a product corresponds to the idealized surface of a three dimensional solid that is topological homeomorphic with the product.
- the surface or a surface of the product can be an exterior surface or an interior surface of the product.
- An exterior surface forms the outermost layer of a product or device.
- An interior surface surrounds an inner cavity of a product or device, such as the inner cavity of a tube.
- both the outside surface of a tube and the inside surface of a tube are part of the surface or a surface of the tube.
- internal surfaces of the product that are not in topological communication with the exterior surface, such as a tube with closed ends, can be excluded as the surface or a surface of a product.
- Preferred surfaces to be chemically modified are the outside surface and surfaces that can contact immune system components.
- the product is porous or has holes in its mean (idealized or surface, the internal faces of passages and holes would not be considered part of the surface or a surface of the product if its opening on the mean surface of the product is less than 5 nm.
- Corresponding product and “similar product,” as used herein, refers a product that has, as far as is practical or possible, the same composition, structure, and construction as a reference product.
- the terms “corresponding” and “similar” can be used for the same meaning with any particular or subgroup of products or other materials described herein.
- a “similar surface modification” refers a surface modification that has, as far as is practical or possible, the same composition, structure, and construction as a reference surface modification.
- Control corresponding product and “control similar product,” as used herein, refers a product that has, as far as is practical or possible, the same composition, structure, and construction as a reference product except for one or more specified parameters.
- a control corresponding product that lacks the chemical modification in reference to a chemically modified product refers to a product that has, as far as is practical or possible, the same composition, structure, and construction as a reference product except for the chemical modification.
- a product prior to chemical modification constitutes a control corresponding product to the chemically modified form of the product.
- control corresponding and “control similar” can be used for the same meaning with any particular or subgroup of products or other materials described herein.
- control similar surface modification refers a surface modification that has, as far as is practical or possible, the same composition, structure, and construction as a reference surface modification except for one or more specified parameters.
- Components that are “control corresponding” or “control similar” relative to a reference component are useful as controls in assays assessing the effect of independent variables.
- Preparation refers to a plurality of the product, compound, or other object or component, each such product, compound, or other object or component having a set of common properties and structure but also having some differences in properties or structure.
- a preparation of capsules with capsules having the same composition, structure, and functional properties can include, for example, capsules having a variance in shape, size, pore size, generally around a desired mean. It is not necessary that such variance be intended or purposely designed, although that is contemplated. Rather, such variance generally is a consequence of the variability in production or preparation of the products, compounds, and other objects and components (as is exemplified by production of capsules).
- transplanting refers to the insertion or grafting into the body of a subject a product or material.
- administering refers to contacting a substance or product to the body of a subject.
- administering a substance or a product includes contacting the skin of a subject and injecting or implanting a substance or product into the subject.
- Chemical compound refers to an organic compound.
- the disclosed compounds for chemically modifying products are examples of chemical compounds.
- Long term refers to a state or situation that extends for longer than days or weeks. Preferred long term effects last several months or years.
- Monitoring refers to any method in the art by which an activity can be measured.
- Providing refers to any method, device, or means of adding a compound or molecule to something, e.g., a method or device known in the art. Examples of providing can include the use of pipettes, pipettemen, syringes, needles, tubing, guns, etc. This can be manual or automated. It can include transfection by any mean or any other means of providing nucleic acids to dishes, cells, tissue, cell-free systems and can be in vitro or in vivo.
- Preventing refers to administering or applying a treatment or therapy prior to the onset of clinical symptoms of a disease or conditions so as to prevent a physical manifestation of aberrations associated with the disease or condition.
- “In need of treatment,” as used herein, refers to a subject that would benefit from the treatment. In some embodiments, it comprises a judgment made by a caregiver (e.g. physician, nurse, nurse practitioner, or individual in the case of humans; veterinarian in the case of animals, including non-human mammals) that a subject requires or will benefit from treatment. This judgment can be made based on a variety of factors that are in the realm of a care giver's expertise, but that includes the knowledge that the subject is ill, or will be ill, as the result of a condition that is treatable by the compounds of the invention.
- a caregiver e.g. physician, nurse, nurse practitioner, or individual in the case of humans; veterinarian in the case of animals, including non-human mammals
- Subject includes, but is not limited to, animals, plants, bacteria, viruses, parasites and any other organism or entity.
- the subject can be a vertebrate, more specifically a mammal (e.g., a human, horse, pig, rabbit, dog, sheep, goat, non-human primate, cow, cat, guinea pig or rodent), a fish, a bird or a reptile or an amphibian.
- the subject can be an invertebrate, more specifically an arthropod (e.g., insects and crustaceans).
- the term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.
- a patient refers to a subject afflicted with a disease or disorder.
- patient includes human and veterinary subjects.
- Treatment and “treating,” as used herein, refer to the medical management of a subject with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder.
- This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder.
- this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
- palliative treatment that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder
- preventative treatment that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder
- supportive treatment that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
- treatment while intended to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder, need not actually result in the cure, ameliorization, stabilization or prevention.
- the effects of treatment can be measured or assessed as described herein and as known in the art
- a cell can be in vitro. Alternatively, a cell can be in vivo and can be found in a subject.
- a “cell” can be a cell from any organism including, but not limited to, a bacterium.
- beneficial effect refers to any effect that is desired.
- beneficial effects include lower foreign body response, improved biocompatibility, and reduced immune response or reaction.
- each instance of the group referred to is chosen independently of the other instances of that group. For example, each instance of the group could be different from every other instance, some other instances, or no other instances of the group. Where multiple groups are referred to, “independently” means that each instance of each given group is chosen independently of the other instances of the respective group and that each of the groups are chosen independently of the other groups. For example, each instance of a first group could be different from every instance, some other instances, or no other instances of a second group (or third, or fourth, etc., group).
- Component as used herein in the context of a product, e.g., medical products, such as medical devices, is a part of a product that is structurally integrated with that product.
- a component may be applied to a substrate or to the surface or a surface of a product, contained within the substance of the product, retained in the interior of the product, or any other arrangement whereby that part is an integral element of the structure of the product.
- the silicone covering surrounding the mechanical part of a pacemaker is a component of the pacemaker.
- a component may be the lumen of a product where the lumen performs some function essential to the overall function of the product.
- the lumen of a tissue expander port is a component of the tissue expander.
- a component can refer to a reservoir or a discrete area within the product specifically adapted for the delivery of a fluid to a surface of the product.
- a reservoir within an implantable drug delivery device is a component of that device.
- phrases “effective amount,” as used herein in the context of a coating, generally refers to the amount of the coating applied to the implant in order to provide one or more clinically measurable endpoints, such as reduced foreign body response compared to an uncoated implant, an implant coated with an unmodified coating, or another suitable control.
- the phrase “effective amount,” as used herein in the context of a cell, capsule, product, device, material, composition, or compound refers to a nontoxic but sufficient amount of the cell, capsule, product, device, material, composition, or compound to provide the desired result.
- the exact amount required may vary from subject to subject, depending on the species, age, and general condition of the subject; the severity of the disease that is being treated; the particular cell, capsule, product, device, material, composition, or compound used; its mode of administration; and other routine variables.
- An appropriate effective amount can be determined by one of ordinary skill in the art using only routine experimentation.
- Singlely modified refers to a modified product that contains one or more covalently attached compounds, non-covalently attached compounds, or both, wherein substantially all of the covalently attached compounds, non-covalently attached compounds, or both are the same compound.
- a singularly modified device includes, for example, a modified device wherein all the modifications are carried out using Z1-Y15 (see below).
- Multiply modified refers to a modified product that contains one or more covalently attached compounds, non-covalently attached compounds, or both, wherein substantially all of the covalently attached compounds, non-covalently attached compounds, or both are not formed using the same compound.
- a multiply modified device includes, for example, a modified device wherein the modifications are carried out using Z2-Y12, Z1-Y15 and Z1-Y19 (see below).
- Capsule refers to a particle having a mean diameter of about 150 ⁇ m to about 5 cm, formed of a cross-linked hydrogel, having a cross-linked hydrogel core that is surrounded by one or more polymeric shells, having one or more cross-linked hydrogel layers, having a cross-linked hydrogel coating, or a combination thereof.
- the capsule may have any shape suitable for, for example, cell encapsulation.
- the capsule may contain one or more cells dispersed in the cross-linked hydrogel, thereby “encapsulating” the cells.
- Reference to “capsules” herein refers to and includes microcapsules unless the context clearly indicates otherwise.
- Preferred capsules have a mean diameter of about 150 ⁇ m to about 8 mm.
- Microcapsule and “microgel,” as used herein, are used interchangeably to refer to a particle or capsule having a mean diameter of about 150 ⁇ m to about 1000 ⁇ m.
- Biomaterial refers to any biological substance, including, but not limited to, tissue, cells, biological micromolecules, such as a nucleotides, amino acids, cofactors, and hormones, biological macromolecules, such as nucleic acids, polypeptides, proteins (for example enzymes, receptors, secretory proteins, structural and signaling proteins, hormones, ligands, etc.), polysaccharides, and/or any combination thereof.
- tissue cells
- biological micromolecules such as a nucleotides, amino acids, cofactors, and hormones
- biological macromolecules such as nucleic acids, polypeptides, proteins (for example enzymes, receptors, secretory proteins, structural and signaling proteins, hormones, ligands, etc.), polysaccharides, and/or any combination thereof.
- Cell refers to individual cells, cell lines, primary cultures, or cultures derived from such cells unless specifically indicated.
- Cell refers to a composition including cells, such as isolated cells, which can be of the same or a different type.
- Cell line refers to a permanently established cell culture that will proliferate indefinitely given appropriate fresh medium and space, thus making the cell line “immortal.”
- Cell strain refers to a cell culture having a plurality of cells adapted to culture, but with finite division potential.
- Cell culture is a population of cells grown on a medium such as agar.
- Cells can be, for example, xenogeneic, autologous, or allogeneic. Cells can also be primary cells. Cells can also be cells derived from the culture and expansion of a cell obtained from a subject. For example, cells can also be stem cells or derived from stem cells. Cells can also be immortalized cells. Cells can also be genetically engineered to express or produce a protein, nucleic acid, or other product.
- Micromalian cell refers to any cell derived from a mammalian subject.
- “Autologous,” as used herein, refers to a transplanted biological material, such as cells, taken from the same individual.
- Allogeneic refers to a transplanted biological material, such as cells, taken from a different individual of the same species.
- Xenogeneic refers to a transplanted biological material, such as cells, taken from a different species.
- Endocrine cell refers to a cell of the endocrine system.
- “Secreting endocrine cell,” as used herein, refers to an endocrine cell that secretes one or more hormones.
- Islet cell refers to an endocrine cell derived from a mammalian pancreas. Islet cells include alpha cells that secrete glucagon, beta cells that secrete insulin and amylin, delta cells that secrete somatostatin, PP cells that secrete pancreatic polypeptide, or epsilon cells that secrete ghrelin. The term includes homogenous and heterogeneous populations of these cells. In preferred embodiments, a population of islet cells contains at least beta cells. In certain embodiments, an islet cell is a human islet cell.
- Hormone-producing cell refers to a cell that produces one or more hormones. Preferred hormone-producing cells produce hormone in response to physiological stimulus, such as the physiological stimulus that cause secretion of the hormone from an endocrine cell that naturally secretes the hormone. Secreting endocrine cells, hormone-producing cells derived from stem cells, and cells genetically engineered to produce hormone are examples of hormone-producing cells.
- Insulin-producing cell refers to a cell that produces insulin. Preferred insulin-producing cells produce insulin in response to glucose levels. Islet beta cells, insulin-producing cells derived from stem cells, and cells genetically engineered to produce insulin are examples of insulin-producing cells.
- Transplant refers to the transfer of a cell, tissue, or organ to a subject from another source. The term is not limited to a particular mode of transfer. Encapsulated cells may be transplanted by any suitable method, such as by injection or surgical implantation.
- Primary cells “primary cell lines,” and “primary cultures,” as used herein, are used interchangeably to refer to cells and cells cultures that have been derived from a subject and allowed to grow in vitro for a limited number of passages, that is, splittings, of the culture.
- Mesenchymal stem cell or “MSC,” as used herein, refer to multipotent stem cells present in or derived from mesenchymal tissue that can differentiate into a variety of cell types, including: osteoblasts, chondrocytes, and adipocytes.
- induced pluripotent stem cells are derived from somatic cells.
- Pluripotency refers to the ability of cells to differentiate into multiple types of cells in an organism.
- pluripotency refers to the ability of cells to differentiate into multiple types of cells in an organism.
- pluripotent stem cells it is meant cells that can self-renew and differentiate to produce all types of cells in an organism.
- multipotency it is meant the ability of cells to differentiate into some types of cells in an organism but not all, typically into cells of a particular tissue or cell lineage.
- Multi-potent cells and “adult stem cells,” as used herein, refer to any type of stem cell that is not derived from an embryo or fetus and generally has a limited capacity to generate new cell types (referred to as “multipotency”) and being committed to a particular lineage.
- “Induced pluripotent stem cell,” as used herein, encompasses pluripotent stem cells, that, like embryonic stem (ES) cells, can be cultured over a long period of time while maintaining the ability to differentiate into all types of cells in an organism, but that, unlike ES cells (which are derived from the inner cell mass of blastocysts), are derived from somatic cells.
- ES embryonic stem
- Analogs and derivatives in the context of chemical compounds, are used herein interchangeably, and refer to a compound having a structure similar to that of a parent compound, but varying from the parent compound by a difference in one or more certain components. (Designation as a parent compound does not mean that the parent compound is used as a starting material or intermediate but is rather a structural relationship.) Analogs or derivatives differ from the parent compound in one or more atoms, functional groups, or substructures, which are replaced with other atoms, groups, or substructures. An analog or derivative can be imagined to be formed, at least theoretically, from the parent compound via some chemical or physical process.
- analog and derivative encompass compounds which retain the same basic ring structure as the parent compound, but possess one or more different substituents on the ring(s).
- an analog or derivative of Z2-Y12 refers to a compound that retains the core of Z2-Y12, e.g., but differs in or more substituents on any of the rings.
- an analog or derivative retains at least, 20, 30, 40, 50, 60, 70, 80, 90, or 100% of a selected activity of a reference compound, e.g., a parent compound.
- “Substantially,” as used herein, specifies an amount of 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more.
- “Click chemistry,” as used herein, refers to chemical reactions used to couple two compounds together which are high yielding, wide in scope, create only byproducts that can be removed without chromatography, are stereospecific, simple to perform, and can be conducted in easily removable or benign solvents.
- Examples of reactions which fulfill these criteria include the nucleophilic ring opening of epoxides and aziridines, non-aldol type carbonyl reactions, including the formation of hydrazones and heterocycles, additions to carbon-carbon multiple bonds, including Michael Additions, and cycloaddition reactions, such as a 1,3-dipolar cycloaddition reaction (i.e., a Huisgen cycloaddition reaction).
- “Substituted,” as used herein, refers to all permissible substituents of the compounds or functional groups described herein.
- the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds.
- Illustrative substituents include, but are not limited to, halogens, hydroxyl groups, or any other organic groupings containing any number of carbon atoms, preferably 1-14 carbon atoms, and optionally include one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats.
- substituents include alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxyl, arylalkyl, substituted arylalkyl, alkoxy, substituted alkoxy, phenoxy, substituted phenoxy, aroxy, substituted aroxy, alkylthio, substituted alkylthio, phenylthio, substituted phenylthio, arylthio, substituted arylthio, cyano, isocyano, substituted isocyano, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, sulfonyl, substituted sulfonyl, sulfonic acid, phosphoryl, substituted phosphoryl, substitute
- Heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. It is understood that “substitution” or “substituted” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, i.e. a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
- substituted refers to a structure, e.g., a chemical compound or a moiety on a larger chemical compound, regardless of how the structure was formed.
- the structure is not limited to a structure made by any specific method.
- Aryl refers to C 5 -C 26 -membered aromatic, fused aromatic, fused heterocyclic, or biaromatic ring systems.
- aryl includes 5-, 6-, 7-, 8-, 9-, 10-, 14-, 18-, and 24-membered single-ring aromatic groups, for example, benzene, naphthalene, anthracene, phenanthrene, chrysene, pyrene, corannulene, coronene, etc.
- Aryl further encompasses polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (i.e., “fused rings”) wherein at least one of the rings is aromatic, e.g., the other cyclic ring or rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocycles.
- substituted aryl refers to an aryl group, wherein one or more hydrogen atoms on one or more aromatic rings are substituted with one or more substituents including, but not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, carbonyl (such as a ketone, aldehyde, carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, imino, alkylthio, sulfate,
- Heterocycle refers to a cyclic radical attached via a ring carbon or nitrogen atom of a monocyclic or bicyclic ring containing 3-10 ring atoms, and preferably from 5-6 ring atoms, consisting of carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(Y) wherein Y is absent or is H, O, C 1 -C 10 alkyl, phenyl or benzyl, and optionally containing 1-3 double bonds and optionally substituted with one or more substituents.
- Heterocyclyl are distinguished from heteroaryl by definition.
- heterocycles include, but are not limited to piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, dihydrofuro[2,3-b]tetrahydrofuran, morpholinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pyranyl, 2H-pyrrolyl, 4H-quinolizinyl, quinuclidinyl, tetrahydrofuranyl, 6H-1,2,5-thiadiazinyl.
- Heterocyclic groups can optionally be substituted with one or more substituents as defined above for alkyl and aryl.
- heteroaryl refers to C 5 -C 26 -membered aromatic, fused aromatic, biaromatic ring systems, or combinations thereof, in which one or more carbon atoms on one or more aromatic ring structures have been substituted with an heteroatom.
- Suitable heteroatoms include, but are not limited to, oxygen, sulfur, and nitrogen.
- heteroaryl includes 5-, 6-, 7-, 8-, 9-, 10-, 14-, 18-, and 24-membered single-ring aromatic groups that may include from one to four heteroatoms, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
- the heteroaryl group may also be referred to as “aryl heterocycles” or “heteroaromatics”.
- Heteroaryl further encompasses polycyclic ring systems having two or more rings in which two or more carbons are common to two adjoining rings (i.e., “fused rings”) wherein at least one of the rings is heteroaromatic, e.g., the other cyclic ring or rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heterocycles, or combinations thereof.
- heteroaryl rings include, but are not limited to, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, is
- substituted heteroaryl refers to a heteroaryl group in which one or more hydrogen atoms on one or more heteroaromatic rings are substituted with one or more substituents including, but not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, carbonyl (such as a ketone, aldehyde, carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, imino, alkylthio, sul
- substituents including
- Alkyl refers to the radical of saturated aliphatic groups, including straight-chain alkyl, alkenyl, or alkynyl groups, branched-chain alkyl, cycloalkyl (alicyclic), alkyl substituted cycloalkylgroups, and cycloalkyl substituted alkyl.
- a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C 1 -C 30 for straight chains, C 3 -C 30 for branched chains), preferably 20 or fewer, more preferably 15 or fewer, most preferably 10 or fewer.
- preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure.
- alkyl (or “lower alkyl”) as used throughout the specification, examples, and claims is intended to include both “unsubstituted alkyls” and “substituted alkyls,” the latter of which refers to alkyl moieties having one or more substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
- substituents include, but are not limited to, halogen, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, a hosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfoxide, sulfonamido, sulfonyl, heterocyclyl, aralkyl, or an aromatic or heteroaromatic moiety.
- carbonyl such as a carboxyl, alkoxycarbonyl, formyl, or an acyl
- thiocarbonyl such as a thio
- lower alkyl as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure. Likewise, “lower alkenyl” and “lower alkynyl” have similar chain lengths. Throughout the application, preferred alkyl groups are lower alkyls. In preferred embodiments, a substituent designated herein as alkyl is a lower alkyl.
- Alkyl includes one or more substitutions at one or more carbon atoms of the hydrocarbon radical as well as heteroalkyls. Suitable substituents include, but are not limited to, halogens, such as fluorine, chlorine, bromine, or iodine; hydroxyl; —NRR′, wherein R and R′ are independently hydrogen, alkyl, or aryl, and wherein the nitrogen atom is optionally quaternized; —SR, wherein R is hydrogen, alkyl, or aryl; —CN; —NO 2 ; —COOH; carboxylate; —COR, —COOR, or —CON(R) 2 , wherein R is hydrogen, alkyl, or aryl; azide, aralkyl, alkoxyl, imino, phosphonate, phosphinate, silyl, ether, sulfonyl, sulfonamido, heterocyclyl, aromatic or heteroaromatic moieties,
- the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
- the substituents of a substituted alkyl may include halogen, hydroxy, nitro, thiols, amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl, sulfoxide, and sulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), haloalkyls, —CN and the like. Cycloalkyls can be substituted in the same manner.
- alkenyl and alkynyl refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively.
- substituted alkenyl refers to alkenyl moieties having one or more substituents replacing one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone.
- substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate,
- substituted alkynyl refers to alkynyl moieties having one or more substituents replacing one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone.
- substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate
- phenyl is art recognized, and refers to the aromatic moiety —C 6 H 5 , i.e., a benzene ring without one hydrogen atom.
- substituted phenyl refers to a phenyl group, as defined above, having one or more substituents replacing one or more hydrogen atoms on one or more carbons of the phenyl ring.
- substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate,
- Amino and “Amine,” as used herein, are art-recognized and refer to both substituted and unsubstituted amines, e.g., a moiety that can be represented by the general formula:
- R, R′, and R′′ each independently represent a hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, —(CH 2 ) m —R′′′, or R and R′ taken together with the N atom to which they are attached complete a heterocycle having from 3 to 14 atoms in the ring structure;
- R′′′ represents a hydroxy group, substituted or unsubstituted carbonyl group, an aryl, a cycloalkyl ring, a cycloalkenyl ring, a heterocycle, or a polycycle; and
- m is zero or an integer ranging from 1 to 8.
- R and R′ can be a carbonyl, e.g., R and R′ together with the nitrogen do not form an imide.
- R and R′ (and optionally R′′) each independently represent a hydrogen atom, substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, or —(CH 2 ) m —R′′′.
- alkylamine refers to an amine group, as defined above, having a substituted or unsubstituted alkyl attached thereto (i.e. at least one of R, R′, or R′′ is an alkyl group).
- Carbonyl as used herein, is art-recognized and includes such moieties as can be represented by the general formula:
- R represents a hydrogen, a substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —(CH 2 ) m —R′′, or a pharmaceutical acceptable salt
- R′ represents a hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl
- X is oxygen and R is defines as above, the moiety is also referred to as a carboxyl group.
- the formula represents a ‘carboxylic acid’.
- the formula represents a ‘formate’.
- the formula represents an “ester”.
- the oxygen atom of the above formula is replaced by a sulfur atom, the formula represents a ‘thiocarbonyl’ group.
- substituted carbonyl refers to a carbonyl, as defined above, wherein one or more hydrogen atoms in R, R′ or a group to which the moiety
- substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfoxide, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, halogen, azide, alkyl
- R iv is an alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, alkylaryl, arylalkyl, aryl, or heteroaryl.
- a straight chain or branched chain alkyl, alkenyl, and alkynyl have 30 or fewer carbon atoms in its backbone (e.g., C 1 -C 30 for straight chain alkyl, C 3 -C 30 for branched chain alkyl, C 2 -C 30 for straight chain alkenyl and alkynyl, C 3 -C 30 for branched chain alkenyl and alkynyl), preferably 20 or fewer, more preferably 15 or fewer, most preferably 10 or fewer.
- preferred cycloalkyls, heterocyclyls, aryls and heteroaryls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure.
- substituted carboxyl refers to a carboxyl, as defined above, wherein one or more hydrogen atoms in R iv are substituted.
- substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl,
- Heteroalkyl refers to straight or branched chain, or cyclic carbon-containing radicals, or combinations thereof, containing at least one heteroatom. Suitable heteroatoms include, but are not limited to, O, N, Si, P and S, wherein the nitrogen, phosphorous and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally quaternized.
- saturated hydrocarbon radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, and homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl.
- unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, and 3-butynyl.
- alkoxyl or “alkoxy,” “aroxy” or “aryloxy,” generally describe compounds represented by the formula —OR v , wherein R v includes, but is not limited to, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, arylalkyl, heteroalkyls, alkylaryl, alkylheteroaryl.
- alkoxyl or “alkoxy” as used herein refer to an alkyl group, as defined above, having an oxygen radical attached thereto.
- Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like.
- An “ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as can be represented by one of —O-alkyl, —O-alkenyl, and —O-alkynyl.
- alkoxy also includes cycloalkyl, heterocyclyl, cycloalkenyl, heterocycloalkenyl, and arylalkyl having an oxygen radical attached to at least one of the carbon atoms, as valency permits.
- substituted alkoxy refers to an alkoxy group having one or more substituents replacing one or more hydrogen atoms on one or more carbons of the alkoxy backbone.
- substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sul
- phenoxy is art recognized, and refers to a compound of the formula —OR v wherein R v is (i.e., —O—C 6 H 5 ).
- R v is (i.e., —O—C 6 H 5 ).
- a phenoxy is a species of the aroxy genus.
- substituted phenoxy refers to a phenoxy group, as defined above, having one or more substituents replacing one or more hydrogen atoms on one or more carbons of the phenyl ring.
- substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sul
- aromatic radicals are represented by —O-aryl or —O-heteroaryl, wherein aryl and heteroaryl are as defined herein.
- substituted aroxy and “substituted aryloxy,” as used interchangeably herein, represent —O-aryl or —O-heteroaryl, having one or more substituents replacing one or more hydrogen atoms on one or more ring atoms of the aryl and heteroaryl, as defined herein.
- substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfoxide, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, —CN
- alkylthio refers to an alkyl group, as defined above, having a sulfur radical attached thereto.
- the “alkylthio” moiety is represented by —S-alkyl.
- Representative alkylthio groups include methylthio, ethylthio, and the like.
- alkylthio also encompasses cycloalkyl groups having a sulfur radical attached thereto.
- substituted alkylthio refers to an alkylthio group having one or more substituents replacing one or more hydrogen atoms on one or more carbon atoms of the alkylthio backbone.
- substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, s
- phenylthio is art recognized, and refers to —S—C 6 H 5 , i.e., a phenyl group attached to a sulfur atom.
- substituted phenylthio refers to a phenylthio group, as defined above, having one or more substituents replacing a hydrogen on one or more carbons of the phenyl ring.
- substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate,
- Arylthio refers to —S-aryl or —S-heteroaryl groups, wherein aryl and heteroaryl as defined herein.
- substituted arylthio represents —S-aryl or —S-heteroaryl, having one or more substituents replacing a hydrogen atom on one or more ring atoms of the aryl and heteroaryl rings as defined herein.
- substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfoxide, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, —CN
- Arylalkyl refers to an alkyl group that is substituted with a substituted or unsubstituted aryl or heteroaryl group.
- Alkylaryl refers to an aryl group (e.g., an aromatic or hetero aromatic group), substituted with a substituted or unsubstituted alkyl group.
- amide or “amido” are used interchangeably, refer to both “unsubstituted amido” and “substituted amido” and are represented by the general formula:
- E is absent, or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, wherein independently of E, R and R′ each independently represent a hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl,
- R and R′ can be a carbonyl, e.g., R and R′ together with the nitrogen do not form an imide.
- R and R′ each independently represent a hydrogen atom, substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, or —(CH 2 ) m —R′.
- E oxygen
- a carbamate is formed. The carbamate cannot be attached to another chemical species, such as to form an oxygen-oxygen bond, or other unstable bonds, as understood by one of ordinary skill in the art.
- E is absent, or E is alkyl, alkenyl, alkynyl, aralkyl, alkylaryl, cycloalkyl, aryl, heteroaryl, heterocyclyl, wherein independently of E, R represents a hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted amine, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —(CH 2 ) m —R′′′, or E and R taken together with the S atom to which they are attached complete a heterocycle having from 3 to 14 atoms in the atom
- substituted sulfonyl represents a sulfonyl in which E, R, or both, are independently substituted.
- substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfamoyl
- sulfonic acid refers to a sulfonyl, as defined above, wherein R is hydroxyl, and E is absent, or E is substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- sulfate refers to a sulfonyl, as defined above, wherein E is absent, oxygen, alkoxy, aroxy, substituted alkoxy or substituted aroxy, as defined above, and R is independently hydroxyl, alkoxy, aroxy, substituted alkoxy or substituted aroxy, as defined above.
- E oxygen
- the sulfate cannot be attached to another chemical species, such as to form an oxygen-oxygen bond, or other unstable bonds, as understood by one of ordinary skill in the art.
- sulfonate refers to a sulfonyl, as defined above, wherein E is oxygen, alkoxy, aroxy, substituted alkoxy or substituted aroxy, as defined above, and R is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted amine, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —(CH 2 ) m —R′′′, R′′′ represents a hydroxy group, substituted or unsubstituted carbonyl group, an aryl, a cycloalkyl ring
- sulfamoyl refers to a sulfonamide or sulfonamide represented by the formula
- E is absent, or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, wherein independently of E, R and R′ each independently represent a hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or
- E is absent, or E is alkyl, alkenyl, alkynyl, aralkyl, alkylaryl, cycloalkyl, aryl, heteroaryl, heterocyclyl, wherein independently of E, R represents a hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted amine, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —(CH 2 ) m —R′′′, or E and R taken together with the S atom to which they are attached complete a heterocycle having from 3 to 14 atoms in the atom
- E is absent, or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, wherein, independently of E, R vi and R vii are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or
- substituted phosphonyl represents a phosphonyl in which E, R vi and R vii are independently substituted.
- substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfoxide,
- phosphoryl defines a phoshonyl in which E is absent, oxygen, alkoxy, aroxy, substituted alkoxy or substituted aroxy, as defined above, and independently of E, R v and R vii are independently hydroxyl, alkoxy, aroxy, substituted alkoxy or substituted aroxy, as defined above.
- E oxygen
- the phosphoryl cannot be attached to another chemical species, such as to form an oxygen-oxygen bond, or other unstable bonds, as understood by one of ordinary skill in the art.
- the substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfoxide, sulfonamido, sulfonyl, heterocyclyl, alkyl, alkenyl, alkynyl
- polyaryl refers to a chemical moiety that includes two or more aryls, heteroaryls, and combinations thereof.
- the aryls, heteroaryls, and combinations thereof, are fused, or linked via a single bond, ether, ester, carbonyl, amide, sulfonyl, sulfonamide, alkyl, azo, and combinations thereof.
- substituted polyaryl refers to a polyaryl in which one or more of the aryls, heteroaryls are substituted, with one or more substituents including, but not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), silyl, ether, ester, thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quarternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl,
- C 3 -C 20 cyclic refers to a substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl that have from three to 20 carbon atoms, as geometric constraints permit.
- the cyclic structures are formed from single or fused ring systems.
- the substituted cycloalkyls, cycloalkenyls, cycloalkynyls and heterocyclyls are substituted as defined above for the alkyls, alkenyls, alkynyls and heterocyclyls, respectively.
- hydroxyl and “hydroxy” are used interchangeably and are represented by —OH.
- thiol and “sulfhydryl” are used interchangeably and are represented by —SH.
- oxo refers to ⁇ O bonded to a carbon atom.
- cyano and “nitrile” are used interchangeably to refer to —CN.
- nitro refers to —NO 2 .
- phosphate refers to —O—PO 3 .
- azide or “azido” are used interchangeably to refer to —N 3 .
- substituted C 1 -C x alkyl refers to alkyl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x alkyl refers to alkyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- substituted C 1 -C x alkylene refers to alkylene groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x alkylene refers to alkylene groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- alkylene refers to a moiety with the formula —(CH 2 ) a —, wherein “a” is an integer from one to ten.
- substituted C 2 -C x alkenyl refers to alkenyl groups having from two to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from two to ten.
- unsubstituted C 2 -C x alkenyl refers to alkenyl groups having from two to x carbon atoms that are not substituted, wherein “x” is an integer from two to ten.
- substituted C 2 -C x alkynyl refers to alkynyl groups having from two to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from two to ten.
- unsubstituted C 2 -C x alkynyl refers to alkynyl groups having from two to x carbon atoms that are not substituted, wherein “x” is an integer from two to ten.
- substituted C 1 -C x alkoxy refers to alkoxy groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x alkoxy refers to alkoxy groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- substituted C 1 -C x alkylamino refers to alkylamino groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x alkylamino refers to alkyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- alkylamine and “alkylamino” are used interchangeably. In any alkylamino, where the nitrogen atom is substituted with one, two, or three substituents, the nitrogen atom can be referred to as a secondary, tertiary, or quartenary nitrogen atom, respectively.
- substituted C 1 -C x alkylthio refers to alkylthio groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x alkylthio refers to alkylthio groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- substituted C 1 -C x carbonyl refers to carbonyl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x carbonyl refers to carbonyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- substituted C 1 -C x carboxyl refers to carboxyl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x carboxyl refers to carboxyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- substituted C 1 -C x amido refers to amido groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x amido refers to amido groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- substituted C 1 -C x sulfonyl refers to sulfonyl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x sulfonyl refers to sulfonyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- substituted C 1 -C x sulfonic acid refers to sulfonic acid groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x sulfonic acid refers to sulfonic acid groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- substituted C 1 -C x sulfamoyl refers to sulfamoyl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x sulfamoyl refers to sulfamoyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- substituted C 1 -C x sulfoxide refers to sulfoxide groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x sulfoxide refers to sulfoxide groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- substituted C 1 -C x phosphoryl refers to phosphoryl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x phosphoryl refers to phosphoryl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- substituted C 1 -C x phosphonyl refers to phosphonyl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten.
- unsubstituted C 1 -C x phosphonyl refers to phosphonyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.
- substituted C 0 -C x sulfonyl refers to sulfonyl groups having from zero to x carbon atoms, wherein, if present, at least one carbon atom is substituted, wherein “x” is an integer from zero to ten.
- unsubstituted C 0 -C x sulfonyl refers to sulfonyl groups having from zero to x carbon atoms that are not substituted, wherein “x” is an integer from zero to ten.
- substituted C 0 -C x sulfonic acid refers to sulfonic acid groups having from zero to x carbon atoms, wherein, if present, at least one carbon atom is substituted, wherein “x” is an integer from zero to ten.
- unsubstituted C 0 -C x sulfonic acid refers to sulfonic acid groups having from zero to x carbon atoms that are not substituted, wherein “x” is an integer from zero to ten.
- substituted C 0 -C x sulfamoyl refers to sulfamoyl groups having from zero to x carbon atoms, wherein, if present, at least one carbon atom is substituted, wherein “x” is an integer from zero to ten.
- unsubstituted C 0 -C x sulfamoyl refers to sulfamoyl groups having from zero to x carbon atoms that are not substituted, wherein “x” is an integer from zero to ten.
- substituted C 0 -C x sulfoxide refers to sulfoxide groups having from zero to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from zero to ten.
- unsubstituted C 0 -C x sulfoxide refers to sulfoxide groups having from zero to x carbon atoms that are not substituted, wherein “x” is an integer from zero to ten.
- substituted C 0 -C x phosphoryl refers to phosphoryl groups having from zero to x carbon atoms, wherein, if present, at least one carbon atom is substituted, wherein “x” is an integer from zero to ten.
- unsubstituted C 0 -C x phosphoryl refers to phosphoryl groups having from zero to x carbon atoms that are not substituted, wherein “x” is an integer from zero to ten.
- substituted C 0 -C x phosphonyl refers to phosphonyl groups having from zero to x carbon atoms, wherein, if present, at least one carbon atom is substituted, wherein “x” is an integer from zero to ten.
- unsubstituted C 0 -C x phosphonyl refers to phosphonyl groups having from zero to x carbon atoms that are not substituted, wherein “x” is an integer from zero to ten.
- C x alkyl refers to alkyl, alkylene, alkenyl, alkynyl, alkoxy,” “C x alkylamino,” “C x alkylthio,” “C x carbonyl,” “C x carboxyl,” “C x amido,” “C x sulfonyl,” “C x sulfonic acid,” “C x sulfamoyl,” “C x phosphoryl,” and “C x phosphonyl” refer to alkyl, alkylene, alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, carbonyl, carboxyl, amido, sulfonyl, sulfonic acid, sulfamoyl, sulfoxide, phosphoryl, and phosphonyl groups, respectively, having x carbon atoms, wherein at least one carbon atom is substitute
- C x alkyl refers to alkyl, alkylene, alkenyl, alkynyl, alkoxy,” “C x alkylamino”, “C x alkylthio,” “C x carbonyl,” “C x carboxyl,” “C x amido,” “C x sulfonyl,” “C x sulfonic acid,” “C x sulfamoyl,” “C x phosphoryl,” and “C x phosphonyl” refer to alkyl, alkylene, alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, carbonyl, carboxyl, amido, sulfonyl, sulfonic acid, sulfamoyl, sulfoxide, phosphoryl, and phosphonyl groups, respectively, having x carbon atoms that are not substituted, where
- C 0 sulfonyl C 0 sulfonic acid
- C 0 sulfamoyl C 0 phosphoryl
- C 0 phosphonyl refer to alkyl, alkylene, alkenyl, alkynyl, alkoxy, alkylamino, alkylthio, carbonyl, carboxyl, amido, sulfonyl, sulfonic acid, sulfamoyl, sulfoxide, phosphoryl, and phosphonyl groups, respectively, having zero carbon atoms that are not substituted.
- Halogen refers to fluorine, chlorine, bromine, or iodine.
- U 1 represents the organic groups alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, substituted alkoxy, phenoxy, substituted phenoxy, aroxy, substituted aroxy, alkylthio, substituted alkylthio, phenylthio, substituted phenylthio, arylthio, substituted arylthio, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, polyaryl, substituted polyaryl, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, substituted heterocyclic, amino acid, poly(ethylene glycol), peptide, and polypeptide group.
- U 2 represents the organic groups alkylamino, dialkylamino, hydroxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, substituted alkoxy, phenoxy, substituted phenoxy, aroxy, substituted aroxy, alkylthio, substituted alkylthio, phenylthio, substituted phenylthio, arylthio, substituted arylthio, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, polyaryl, substituted polyaryl, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, substituted heterocyclic, amino acid, poly(ethylene glycol), peptide,
- U 3 represents the organic groups alkylamino, dialkylamino, hydroxy, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, substituted alkoxy, phenoxy, substituted phenoxy, aroxy, substituted aroxy, alkylthio, substituted alkylthio, phenylthio, substituted phenylthio, arylthio, substituted arylthio, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, polyaryl, substituted polyaryl, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, substituted heterocyclic, amino acid, poly(ethylene glycol), peptide, and polypeptide
- U 4 represents the organic groups alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C 3 -C 20 cyclic, substituted C 3 -C 20 cyclic, heterocyclic, and substituted heterocyclic.
- Q 1 represents the organic groups arylalkyl and substituted arylalkyl.
- Q 2 represents the organic groups sulfonyl, substituted sulfonyl, sulfonic acid, phosphoryl, substituted phosphoryl, phosphonyl, and substituted phosphonyl.
- Q 3 represents the organic group poly(lactic-co-glycolic acid).
- Q 4 represents the organic groups phenyl and substituted phenyl.
- Q 5 represents the organic groups alkylamino, dialkylamino, and hydroxy.
- Q 6 represents the organic groups aroxy, substituted aroxy, carbonyl, substituted carbonyl, and poly(ethylene glycol).
- Q 7 represents the organic groups alkylthio, substituted alkylthio, arylthio, substituted arylthio, phenoxy, substituted phenoxy, phenylthio, substituted phenylthio, polyaryl, and substituted polyaryl.
- Q 8 represents the organic groups amino acid, peptide, and polypeptide group.
- groups Q 1 , Q 2 , Q 3 , or any combination thereof can be used along with any one of U 1 , U 2 , and U 3 .
- U 1 can be combined with Q 1 , with Q 2 , with Q 3 , with Q 1 and Q 2 , with Q 1 and Q 3 , with Q 2 and Q 3 , and with Q 1 , Q 2 , and Q 3 .
- Such combinations can be referred to as U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , and U 1 +Q 1 +Q 2 +Q 3 , respectively.
- U 2 can be combined with Q 1 , with Q 2 , with Q 3 , with Q 1 and Q 2 , with Q 1 and Q 3 , with Q 2 and Q 3 , and with Q 1 , Q 2 , and Q 3 .
- Such combinations can be referred to as U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , and U 2 +Q 1 +Q 2 +Q 3 , respectively.
- U 3 can be combined with Q 1 , with Q 2 , with Q 3 , with Q 1 and Q 2 , with Q 1 and Q 3 , with Q 2 and Q 3 , and with Q 1 , Q 2 , and Q 3 .
- Such combinations can be referred to as U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , and U 3 +Q 1 +Q 2 +Q 3 , respectively.
- groups Q 1 , Q 2 , Q 3 , Q 5 , or any combination thereof, can be used along with U 1 .
- U 1 can be combined with Q 1 , with Q 2 , with Q 3 , with Q 5 , with Q 1 and Q 2 , with Q 1 and Q 3 , with Q 1 and Q 5 , with Q 2 and Q 3 , with Q 2 and Q 5 , with Q 3 and Q 5 , with Q 1 , Q 2 , and Q 3 , with Q 1 , Q 2 , and Q 5 , with Q 1 , Q 3 , and Q 5 , with Q 2 , Q 3 , and Q 5 , and with Q 1 , Q 2 , Q 3 , and Q 5 , and with Q 1 , Q 2 , Q 3 , and Q 5 .
- Such combinations can be referred to as U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 5 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 1 +Q 5 , U 1 +Q 2 +Q 3 , U 1 +Q 2 +Q 5 , U 1 +Q 3 +Q 5 , U 1 +Q 1 +Q 2 +Q 3 , U 1 +Q 1 +Q 2 +Q 3 , U 1 +Q 1 +Q 2 +Q 5 , U 1 +Q 1 +Q 3 +Q 5 , U 1 +Q 2 +Q 3 +Q 5 , respectively.
- groups Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , Q 6 , Q 7 , Q 8 or any combination thereof, can be used along with U 4 .
- U 4 can be combined with Q 1 , with Q 2 , with Q 3 , with Q 4 , with Q 5 , with Q 6 , with Q 7 , with Q 5 , with Q 1 +Q 2 , with Q 1 +Q 3 , with Q 1 +Q 4 , with Q 1 +Q 5 , with Q 1 +Q 6 , with Q 1 +Q 7 , with Q 1 +Q 5 , with Q 2 +Q 3 , with Q 2 +Q 4 , with Q 2 +Q 5 , with Q 2 +Q 6 , with Q 2 +Q 7 , with Q 2 +Q 8 , with Q 3 +Q 4 , with Q 3 +Q 5 , with Q 3 +Q 6 , with Q 3 +Q 7 , with Q 3 +Q 8 , with Q 3 +Q 4 , with Q 3 +Q 5 , with Q
- Such combinations can be referred to as U 4 +Q 1 , U 4 +Q 2 , U 4 +Q 3 , U 4 +Q 4 , U 4 +Q 5 , U 4 +Q 6 , U 4 +Q 7 , U 4 +Q 8 , U 4 +Q 1 +Q 2 , U 4 +Q 1 +Q 3 , U 4 +Q 1 +Q 4 , U 4 +Q 1 +Q 5 , U 4 +Q 1 +Q 6 , U 4 +Q 1 +Q 7 , U 4 +Q 1 +Q 8 , U 4 +Q 2 +Q 3 , U 4 +Q 2 +Q 4 , U 4 +Q 2 +Q 5 , U 4 +Q 2 +Q 6 , U 4 +Q 2 +Q 7 , U 4 +Q 2 +Q 8 , U 4 +Q 3 +Q 4 , U 4 +Q 3 +Q 4 , U 4 +Q 3 +Q 4 , U 4 +Q 3 +Q 5 , U 4 +Q 3 +Q 6 , U 4 +Q 3 +Q 8 ,
- J 1 represents the organic groups substituted or unsubstituted C 1 -C 10 alkyl, C 1 -C 10 alkylene, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 1 -C 10 alkoxy, C 1 -C 10 alkylamino, C 1 -C 10 alkylthio, C 1 -C 10 carbonyl, C 1 -C 10 carboxyl, C 1 -C 10 amido, C 1 -C 10 sulfonyl, C 1 -C 10 sulfonic acid, C 1 -C 10 sulfamoyl, C 1 -C 10 sulfoxide, C 1 -C 10 phosphoryl, C 1 -C 10 phosphonyl, C 1 -C 9 alkyl, C 1 -C 9 alkylene, C 2 -C 9 alkenyl, C 2 -C 9 alkynyl, C 1 -C 9 alkoxy,
- J 1 represents the organic groups substituted or unsubstituted C 1 -C 10 alkyl, C 1 -C 10 alkylene, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 1 -C 10 alkoxy, C 1 -C 10 alkylamino, C 1 -C 10 alkylthio, C 1 -C 9 alkyl, C 1 -C 9 alkylene, C 2 -C 9 alkenyl, C 2 -C 9 alkynyl, C 1 -C 9 alkoxy, C 1 -C 9 alkylamino, C 1 -C 9 alkylthio, C 1 -C 5 alkyl, C 1 -C 5 alkylene, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 1 -C 8 alkoxy, C 1 -C 8 alkylamino, C 1 -C 8 alkylthio, C 1 -
- the surface(s) and face(s) of the product to be modified can be those that, when the device is administered to (e.g., implanted in) a subject, would be in contact with fluid, cells, or other components of the subjects body.
- the compounds are represented by the general formula:
- X is oxygen, sulfur, NR 2 , or another group compatible with attachment or coupling of the compound to a product or surface;
- R 1 is hydrogen, or an organic grouping containing any number of carbon atoms, preferably 1-30 carbon atoms, more preferably 1-20 carbon atoms, more preferably 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R 1 organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ); and
- R 2 is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R 2 organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- X is preferably oxygen, sulfur, or NR 2 .
- R 1 is, independently in one or more sites of chemical modification
- A is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 );
- B, and C are, independently, absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- ⁇ is an integer from, as valency permits, 0 to 30.
- X is preferably oxygen, sulfur, or NR 2 .
- R 1 is, independently in one or more sites of chemical modification
- R 3 is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R 3 organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- R b is absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R b organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- R 1 , R 2 , R 3 , R 4 , R 5 , R b , A, B, and C can be, independently, absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R 1 , R 2 , R 3 , R 4 , R 5 , R b , A, B, and C organic groupings being those present in U 1 +Q 1 +Q 2 +Q 3 , U 1 +Q 5 , U 1 +Q 1 +Q 5 , U 1 +Q 2 +Q 5 , U 1 +Q 3 +Q 5 , U
- R 1 , R 2 , R 3 , R 4 , R 5 , R b , A, B, and C can be, independently, absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R 1 , R 2 , R 3 , R 4 , R 5 , R b , A, B, and C organic groupings being those present in U 4 , U 4 +Q 1 , U 4 +Q 2 , U 4 +Q 3 , U 4 +Q 4 , U 4 +Q 5 , U 4 +Q 6 , U 4 +Q 7
- a and R 3 can be, independently, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- B, C, and R b can be, independently, absent, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- a and R 3 can be, independently, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J 1 .
- a and R 3 can be, independently, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J 2 .
- B, C, and R b independently in combination with any embodiments of any other relevant substituent classes, B, C, and R b can be, independently, absent, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J 1 .
- B, C, and R b independently in combination with any embodiments of any other relevant substituent classes, B, C, and R b can be, independently, absent, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J 2 .
- a and R 3 can be, independently,
- z is an integer from 0-11; wherein w is an integer from 0-9; wherein k is an integer from 0 to 20;
- R d are independently B, C, —B(—C) ⁇ , R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- X d are independently absent, O, or S;
- R c is B, C, —B(—C) ⁇ , R b , absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 );
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently B, C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently B, C, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- z is an integer from 0-11; wherein w is an integer from 0-9; wherein k is an integer from 0 to 20;
- R d are independently C, R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- X d are independently absent, O, or S;
- R c is C, R b , absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 );
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, R b , absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- z is an integer from 0-11; wherein w is an integer from 0-9; wherein k is an integer from 0 to 20;
- R d are independently C, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- X d are independently absent, O, or S;
- R c is C, absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 );
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- z is an integer from 0-11; wherein w is an integer from 0-9; wherein k is an integer from 0 to 20;
- R d are independently U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- X d are independently absent, O, or S;
- R c is absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 );
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- a and R 3 can be, independently,
- z is an integer from 0-11; wherein w is an integer from 0-9;
- R d are independently B, C, —B(—C) ⁇ , R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently B, C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- z is an integer from 0-11; wherein w is an integer from 0-9;
- R d are independently C, R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, R b , absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- z is an integer from 0-11; wherein w is an integer from 0-9;
- R d are independently C, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- z is an integer from 0-11; wherein w is an integer from 0-9;
- R d are independently U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- a and R 3 can be, independently,
- w is an integer from 0-9;
- R d are independently B, C, —B(—C) ⁇ , R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently B, C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- w is an integer from 0-9;
- R d are independently C, R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, R b , absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- w is an integer from 0-9;
- R d are independently C, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- w is an integer from 0-9;
- R d are independently U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- a and R 3 can be, independently,
- w is an integer from 0-9;
- R d are independently B, C, —B(—C) ⁇ , R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, wherein one, two, three, or four of R 12 , R 13 , R 14 , R 15 , and R 16 are N and the others are C, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently B, C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- w is an integer from 0-9;
- R d are independently C, R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, wherein one, two, three, or four of R 12 , R 13 , R 14 , R 15 , and R 16 are N and the others are C, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, R b , absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- w is an integer from 0-9;
- R d are independently C, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, wherein one, two, three, or four of R 12 , R 13 , R 14 , R 15 , and R 16 are N and the others are C, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently C, absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- w is an integer from 0-9;
- R d are independently U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , and R 16 are independently C or N, wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, wherein one, two, three, or four of R 12 , R 13 , R 14 , R 15 , and R 16 are N and the others are C, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency; and
- R 18 are independently absent, —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein R 20 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- a and R 3 can be, independently,
- k is an integer from 0 to 20;
- X d are independently absent, O, or S;
- R c is B, C, —B(—C) ⁇ , R b , absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently B, C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- k is an integer from 0 to 20;
- X d are independently absent, O, or S;
- R c is C, R b , absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- k is an integer from 0 to 20;
- X d are independently absent, O, or S;
- R c is C, absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- k is an integer from 0 to 20;
- X d are independently absent, O, or S;
- R c is absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- a and R 3 can be, independently,
- k is an integer from 0 to 20;
- X d are independently O or S;
- R c is B, C, —B(—C) ⁇ , R b , absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently B, C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- k is an integer from 0 to 20;
- X d are independently O or S;
- R is C, R b , absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- k is an integer from 0 to 20;
- X d are independently O or S;
- R c is C, absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- k is an integer from 0 to 20;
- X d are independently O or S;
- R c is absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- a and R 3 can be, independently,
- k is an integer from 1 to 20;
- R c is B, C, —B(—C) ⁇ , R b , U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently B, C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- B independently in combination with any embodiments of any other relevant substituent classes, B can be
- k is an integer from 1 to 20;
- R c is C, R b , absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, R b , hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- R b independently in combination with any embodiments of any other relevant substituent classes, R b can be
- k is an integer from 1 to 20;
- R c is C, absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently C, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- k is an integer from 1 to 20;
- R c is absent, hydrogen, U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 3 ); and
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 are independently hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- A is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
- each k is, independently, an integer from 0 to 20;
- R c is B
- each X d is, independently, absent, O, or S;
- each R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 is, independently, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J 1 ;
- each X d is O; and each R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 is, independently, hydrogen, C 1 -C 3 alkyl, C 1 -C 3 alkylene, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, C 1 -C 3 alkoxy, C 1 -C 3 alkylamino, C 1 -C 3 alkylthio;
- each X d is O; and each R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 is hydrogen; and
- A is —CH 2 —CH 2 —(O—CH 2 —CH 2 ) 3 —;
- B and C are, independently, absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- B is
- each w is, independently, an integer from 0-9;
- R d is C
- each R 12 , R 13 , R 14 , R 15 , and R 16 is, independently, C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 16 are double or single according to valency, and wherein R 12 to R 16 are bound to none, one, or two hydrogens according to valency;
- w is 1, 2, 3, or 4; and none, one, two, three, four, or five of R 12 , R 13 , R 14 , R 15 , and R 16 are N, none, one, two, three, four, or five of R 12 , R 13 , R 14 , R 15 , and R 16 is O, and the others are C;
- w is 1 or 2; and one, two, or three of R 12 , R 13 , R 14 , R 15 , and R 16 are N, none or one of R 12 , R 13 , R 14 , R 15 , and R 16 is O, and the others are C;
- w is 1 or 2; and three of R 12 , R 13 , R 14 , R 15 , and R 16 are N, none of R 12 , R 13 , R 14 , R 15 , and R 16 is O, and the others are C; and
- R 4 is hydrogen and R 5 is C;
- A is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- each C is, independently, absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- C is
- z is an integer from 0-11;
- each R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 is, independently, C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency;
- each R 18 is, independently, absent, —(CR 19 R 19 ) p —, or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein each p and q is, independently, an integer from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein each R 20 is, independently, J 2 ;
- each R d is, independently, J 1 ;
- each R 18 is, independently, absent, —(CR 19 R 19 ) p —, or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein each p is, independently, 0, 1, 2, or 3, each q is, independently, 0, 1, or 2, and X b is O; and R d is, independently, C 1 -C 2 carbonyl, C 1 -C 2 carboxyl, C 1 -C 2 amino, C 1 -C 2 amido, C 1 -C 2 sulfon
- each R 18 is, independently, absent, —(CR 19 R 19 ) p —, or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein each p is, independently, 0 or 1, each q is, independently, 0 or 1, and X b is O; and R d is, independently, C 1 carbonyl, C 1 carboxyl, C 1 amino, C 1 amido, C 1 sulfonyl, C 1 sulfonic acid, C 2 phosphoryl, or C 2 phosphonyl; and
- each R 18 is, independently, absent, —(CR 19 R 19 ) p —, or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein each p is, independently, 0 or 1, each q is, independently, 0 or 1, and X b is O; and R d is, independently, C 1 carbonyl, C 1 carboxyl, C 1 amino, or C 1 sulfonyl; and
- A is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- B is absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ).
- each R 4 , R 5 , and C are, independently,
- each z is, independently, an integer from 0-11; wherein each w is, independently, an integer from 0-9; wherein each k is, independently, an integer from 0 to 20;
- R c is B
- R c and R d are C
- each X d is, independently, absent, O, or S;
- each R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 is, independently, C, O, N, S, S(O), or S(O) 2 , wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- each R 18 is, independently, absent, —(CR 19 R 19 ) p —, or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein each p and q is, independently, an integer from 0 to 5, wherein X b is absent, —O—, —S—, —S(O)—, —S(O) 2 —, or NR 20 , wherein each R 19 is, as valency permits, independently absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, or —NR 20 , wherein each R 20 is, independently, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- each R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 is, independently, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- each R 20 is, independently, J 2 .
- each R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 is, independently, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J 1 .
- none, one, two, three, four, five, or six of R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are N, none, one, two, three, four, five, or six of R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 is O, and the others are C.
- none, one, two, three, four, or five of R 12 , R 13 , R 14 , R 15 , and R 16 are N, none, one, two, three, four, or five of R 12 , R 13 , R 14 , R 15 , and R 16 is O, and the others are C.
- none, one, two, or three of R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are N, none, one, two, or three of R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 is O, and the others are C.
- in B three of R 12 , R 13 , R 14 , R 15 , and R 16 are N, none of R 12 , R 13 , R 14 , R 15 , and R 16 is O, and the others are C.
- R 3 and A are —CH 2 —Ar— or —CH 2 —CH 2 —(O—CH 2 —CH 2 ) 3 —;
- R 2 is hydrogen;
- R 4 and C are hydrogen, methyl, or —CH 2 —OH; and
- R 5 and C are methyl, —COCH 3 , —CH 2 —N(CH 2 —CH 3 ) 2 ,
- R 4 is hydrogen; and R 5 and C are
- R 4 is hydrogen; and R 5 and C are
- R 5 and C are methyl, —COCH 3 , or —CH 2 —N(CH 2 —CH 3 ) 2 .
- X is oxygen or NR 2 , wherein R 2 is hydrogen, methyl, or —CH 2 —CH 3 ; and R 1 is —CH 2 —CH 2 —CH 2 —CH 2 —OH, —CH 2 —CH 2 —(O—CH 2 —CH 2 ) n —O—CH 3 , —CH 2 —CH 2 —O—CH 2 —CH 2 —OH, —(CH 2 —CH 2 ) 3 —NH—CH 3 ,
- n is an integer from 3 to 16.
- R c can be B, C, —B(—C) ⁇ , R b , amino, hydroxyl, thiol, oxo, phosphate, or J 1 .
- R c can be B, C, —B(—C) ⁇ , R b , amino, hydroxyl, thiol, oxo, phosphate, or J 2 .
- R c can be B, C, —B(—C) ⁇ , R b , amino, hydroxyl, thiol, oxo, phosphate, or substituted or unsubstituted C 1 -C 5 alkyl, C 1 -C 5 alkylene, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, C 1 -C 5 alkoxy, C 1 -C 5 alkylamino, C 1 -C 5 alkylthio, C 1 -C 5 carbonyl, C 1 -C 5 carboxyl, C 1 -C 8 amido, C 1 -C 8 sulfonyl, C 1 -C 5 sulfonic acid, C 1 -C 5 sulfamoyl, C 1 -C 5 sulfoxide, C 1 -C 5 phosphoryl, C 1
- R c can be B, C, —B(—C) ⁇ , R b , amino, hydroxyl, thiol, oxo, phosphate, or substituted or unsubstituted C 1 -C 5 alkyl, C 1 -C 5 alkylene, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, C 1 -C 5 alkoxy, C 1 -C 5 alkylamino, C 1 -C 5 alkylthio, C 1 -C 4 alkyl, C 1 -C 4 alkylene, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylamino, C 1 -C 4 alkylthio, C 1 -C 3 alkyl, C 1 -C 3 alkyl, C 1 -C 3 alkyl, C 1 -C 3 alkyl, C 1 -C
- R c can be B, C, —B(—C) ⁇ , R b , amino, hydroxyl, thiol, oxo, phosphate, or substituted or unsubstituted C 1 -C 4 alkyl, C 1 -C 4 alkylene, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylamino, C 1 -C 4 alkylthio, C 1 -C 4 carbonyl, C 1 -C 4 carboxyl, C 1 -C 4 amino, C 1 -C 4 amido, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonic acid, C 1 -C 4 sulfamoyl, C 1 -C 4 sulfoxide, C 1 -
- R c can be B, C, —B(—C) ⁇ , R b , amino, hydroxyl, thiol, oxo, phosphate, or substituted or unsubstituted C 1 -C 4 alkyl, C 1 -C 4 alkylene, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylamino, C 1 -C 4 alkylthio, C 1 -C 3 alkyl, C 1 -C 3 alkylene, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, C 1 -C 3 alkoxy, C 1 -C 3 alkylamino, C 1 -C 3 alkylthio, C 1 -C 2 alkyl, C 1 -C 2 alkyl, C 1 -C 2 alky
- R c can be B, C, —B(—C) ⁇ , R b , amino, hydroxyl, thiol, oxo, phosphate, or substituted or unsubstituted C 1 -C 3 alkyl, C 1 -C 3 alkylene, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, C 1 -C 3 alkoxy, C 1 -C 3 alkylamino, C 1 -C 3 alkylthio, C 1 -C 3 carbonyl, C 1 -C 3 carboxyl, C 1 -C 3 amino, C 1 -C 3 amido, C 1 -C 3 sulfonyl, C 1 -C 3 sulfonic acid, C 1 -C 3 sulfamoyl, C 1 -C 3 sulfoxide, C 1 -
- R c can be B, C, —B(—C) ⁇ , R b , amino, hydroxyl, thiol, oxo, phosphate, or substituted or unsubstituted C 1 -C 3 alkyl, C 1 -C 3 alkylene, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, C 1 -C 3 alkoxy, C 1 -C 3 alkylamino, C 1 -C 3 alkylthio, C 1 -C 2 alkyl, C 1 -C 2 alkylene, C 1 -C 2 alkoxy, C 1 -C 2 alkylamino, C 1 -C 2 alkylthio, C 10 alkyl, C 10 alkylene, C 10 alkenyl, C 10 alkynyl, C 10 alkoxy, C 10 alkylamino,
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 can be, independently, R b , hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J 1 .
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 can be, independently, R b , hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J 2 .
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 can be, independently, R b , hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or substituted or unsubstituted C 1 -C 5 alkyl, C 1 -C 5 alkylene, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, C 1 -C 5 alkoxy, C 1 -C 5 alkylamino, C 1 -C 5 alkylthio, C 1 -C 5 carbonyl, C 1 -C 5 carboxyl, C 1 -C 8 amido, C 1 -C 8 sulfonyl, C 1 -C 5
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 can be, independently, R b , hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or substituted or unsubstituted C 1 -C 5 alkyl, C 1 -C 5 alkylene, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, C 1 -C 5 alkoxy, C 1 -C 5 alkylamino, C 1 -C 5 alkylthio, C 1 -C 4 alkyl, C 1 -C 4 alkylene, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 can be, independently, R b , hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or substituted or unsubstituted C 1 -C 4 alkyl, C 1 -C 4 alkylene, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylamino, C 1 -C 4 alkylthio, C 1 -C 4 carbonyl, C 1 -C 4 carboxyl, C 1 -C 4 amino, C 1 -C 4 amido, C 1 -C 4 sulfony
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 can be, independently, R b , hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or substituted or unsubstituted C 1 -C 4 alkyl, C 1 -C 4 alkylene, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylamino, C 1 -C 4 alkylthio, C 1 -C 3 alkyl, C 1 -C 3 alkylene, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, C 1 -C 3
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 can be, independently, R b , hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or substituted or unsubstituted C 1 -C 3 alkyl, C 1 -C 3 alkylene, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, C 1 -C 3 alkoxy, C 1 -C 3 alkylamino, C 1 -C 3 alkylthio, C 1 -C 3 carbonyl, C 1 -C 3 carboxyl, C 1 -C 3 amino, C 1 -C 3 amido, C 1 -C 3 sulfony
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , and R 28 can be, independently, R b , hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or substituted or unsubstituted C 1 -C 3 alkyl, C 1 -C 3 alkylene, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, C 1 -C 3 alkoxy, C 1 -C 3 alkylamino, C 1 -C 3 alkylthio, C 1 -C 2 alkyl, C 1 -C 2 alkylene, C 1 -C 2 alkoxy, C 1 -C 2 alkylamino, C 1 -C 2 al
- 6 can be an integer from 1 to 30, 2 to 30, 3 to 30, 4 to 30, 5 to 30, 6 to 30, 7 to 30, 8 to 30, 9 to 30, 10 to 30, 11 to 30, 12 to 30, 13 to 30, 14 to 30, 15 to 30, 16 to 30, 17 to 30, 18 to 30, 19 to 30, 20 to 30, 21 to 30, 22 to 30, 23 to 30, 24 to 30, 25 to 30, 26 to 30, 27 to 30, 28 to 30, 29 to 30, 1 to 29, 2 to 29, 3 to 29, 4 to 29, 5 to 29, 6 to 29, 7 to 29, 8 to 29, 9 to 29, 10 to 29, 11 to 29, 12 to 29, 13 to 29, 14 to 29, 15 to 29, 16 to 29, 17 to 29, 18 to 29, 19 to 29, 20 to 29, 21 to 29, 22 to 29, 23 to 29, 24 to 29, 25 to 29, 26 to 29, 27 to 29, 28 to 29, 1 to 29, 26 to 29, 27 to 29, 28 to 29, 1 to 29, 26 to 29, 27 to 29, 28 to 29, 1 to 29, 26 to 29, 27 to 29, 28 to 29, 1 to 29, 26 to 29, 27 to 29, 28 to 29, 1 to 29, 26 to 29, 27 to 29, 28 to 29, 1 to 29, 26 to 29, 27 to 29, 28 to 29, 1 to 29, 26 to
- 6 can be an integer from 1 to 10, 2 to 10, 3 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10, 9 to 10, 1 to 9, 2 to 9, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 1 to 8, 2 to 8, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 1 to 7, 2 to 7, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 1 to 6, 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2.
- ⁇ can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- ⁇ can be an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2.
- ⁇ can be 1, 2, 3, 4, or 5.
- k can be an integer from 1 to 20, 2 to 20, 3 to 20, 4 to 20, 5 to 20, 6 to 20, 7 to 20, 8 to 20, 9 to 20, 10 to 20, 11 to 20, 12 to 20, 13 to 20, 14 to 20, 15 to 20, 16 to 20, 17 to 20, 18 to 20, 19 to 20, 1 to 19, 2 to 19, 3 to 19, 4 to 19, 5 to 19, 6 to 19, 7 to 19, 8 to 19, 9 to 19, 10 to 19, 11 to 19, 12 to 19, 13 to 19, 14 to 19, 15 to 19, 16 to 19, 17 to 19, 18 to 19, 1 to 18, 2 to 18, 3 to 18, 4 to 18, 5 to 18, 6 to 18, 7 to 18, 8 to 18, 9 to 18, 10 to 18, 11 to 18, 12 to 18, 13 to 18, 14 to 18, 15 to 18, 16 to 18, 17 to 18, 1 to 17, 2 to 17, 3 to 17, 4 to 17, 5 to 17, 6 to 17, 7 to 17, 8 to 17, 9 to 17, 10 to 17, 11 to 17, 12 to 17, 13 to 17, 14 to 17, 15 to 17, 16 to 17, 1 to 16, 2 to 16, 3 to 16, 4 to 16,
- k can be an integer from 1 to 10, 2 to 10, 3 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10, 9 to 10, 1 to 9, 2 to 9, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 1 to 8, 2 to 8, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 1 to 7, 2 to 7, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 1 to 6, 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2.
- k can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
- w can be an integer from 1 to 9, 2 to 9, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 1 to 8, 2 to 8, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 1 to 7, 2 to 7, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 1 to 6, 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2.
- w can be 1, 2, 3, 4, 5, 6, 7, 8, or 9.
- w can be an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. In preferred embodiments, w is 1, 2, 3, 4, or 5.
- z can be an integer from 1 to 11, 2 to 11, 3 to 11, 4 to 11, 5 to 11, 6 to 11, 7 to 11, 8 to 11, 9 to 11, 10 to 11, 1 to 10, 2 to 10, 3 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10, 9 to 10, 1 to 9, 2 to 9, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 1 to 8, 2 to 8, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 1 to 7, 2 to 7, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 1 to 6, 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2.
- z can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11.
- z can be an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2.
- z can be 1, 2, 3, 4, or 5.
- p and q can be, independently, an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2.
- p and q can be, independently, 1, 2, 3, 4, or 5.
- R 1 is, independently in one or more sites of chemical modification
- a is an integer from 1 to 30, z is an integer from 0-5, n is an integer from 1 to 12, m is an integer from 3 to 16,
- R a is independently selected from U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 +Q 2 +Q 3 ), and
- R 2 is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R 2 organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 3 ); and
- R 3 , R 4 , and R 5 are, independently, hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R 3 , R 4 , and R 5 organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 +Q 2 +Q 3 ).
- the surface or a surface of the product includes one or more covalent modifications defined by Formula I
- X is oxygen, sulfur, NR 2 , or another group compatible with attachment or coupling of the compound to a product or surface;
- R 1 is, independently in the one or more modified monomers
- k is an integer from 1 to 10; wherein z is an integer from 0 to 5; wherein w is an integer from 0 to 4; wherein X d is absent, O or S;
- R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 31 , R 32 , and R 33 are independently hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 2 );
- R 29 is C or Si
- X g and R 30 are independently U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 2 ); and
- R a and R c are independently U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic, heterocyclic ring or
- R 4 , R 5 , or both are, independently, hydrogen, alkyl, substituted alkyl, alkoxy, amino, alkylamino, dialkylamino, hydroxy, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, carbonyl, substituted carbonyl, carbinol,
- R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are, independently, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 );
- R 6 , R 9 , R 10 , and R 11 are independently present or absent according to valency, and wherein the ring bonds are double or single according to valency;
- R d and R e are each independently U 2 , U 2 +Q 1 , U 2 +Q 2 , U 2 +Q 3 , U 2 +Q 1 +Q 2 , U 2 +Q 1 +Q 3 , U 2 +Q 2 +Q 3 , U 2 +Q 1 +Q 2 +Q 3 , U 3 , U 3 +Q 1 , U 3 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 2 , U 3 +Q 3 , U 3 +Q 1 +Q 2 , U 3 +Q 1 +Q 3 , U 3 +Q 2 +Q 3 , or U 3 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 3 +Q 1 ); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, or S, wherein the bonds between adjacent R 12 to R 17 are double or single according to valency, and wherein R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 is independently —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, wherein p and q are independently integers from 0 to 5, wherein X b is absent, —O—, —S—, —SO 2 —, or NR 2 , wherein each R 19 is independently absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, —NR 2 , wherein R 2 is U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 );
- R 4 , and R 5 are not both hydrogen; wherein at least one R b or R c is defined by Formula III;
- R 2 is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 ).
- X is preferably oxygen, sulfur, or NR 2 .
- z in Formula VI is an integer from 0-3;
- R d is independently amino, hydroxyl, thiol, oxo, phosphate, or substituted or unsubstituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 1 -C 6 alkylthio;
- R 12 , R 13 , R 14 , R 15 , R 16 , and R 17 are independently C, O, N, or S, where the bonds between adjacent R 12 to R 17 are double or single according to valency, and where R 12 to R 17 are bound to none, one, or two hydrogens according to valency; and
- R 18 is independently —(CR 19 R 19 ) p — or —(CR 19 R 19 ) p —X b —(CR 19 R 19 ) q —, where p and q are independently integers from 0 to 3, where X b is absent, —O—, —S—, —SO 2 —, or NR 2 , where each R 19 is independently absent, hydrogen, ⁇ O, ⁇ S, —OH, —SH, —NR 2 , where R 2 is substituted or unsubstituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 1 -C 6 alkylthio.
- z in Formula VI is 2, R 12 is N, R 13 , R 14 , R 15 , R 16 , or R 17 is S, both R d are oxo and are bonded to the S, and all of the bonds between adjacent R 12 to R 17 are single.
- z in Formula VI is 2, both R d are oxo and are bonded to R 15 , R 12 is N, R 15 is S, and all of the bonds between adjacent R 12 to R 17 are single.
- z in Formula VI is 2, both R d are oxo and are bonded to R 15 , R 12 is N, R 15 is S, and all of the bonds between adjacent R 12 to R 17 are single, X b is absent, q is 0, p is 1, and each R 19 is hydrogen.
- z in Formula VI is 1, R ed is amino, and three of the bonds between adjacent R 12 to R 17 are double and three of the bonds between adjacent R 12 to R 17 are single.
- z in Formula VI is 1, R d is amino and is bonded to R 15 , and three of the bonds between adjacent R 12 to R 17 are double and three of the bonds between adjacent R 12 to R 17 are single.
- z in Formula VI is 1, R d is amino and is bonded to R 15 , and three of the bonds between adjacent R 12 to R 17 are double and three of the bonds between adjacent R 12 to R 17 are single, X b is absent, p is 0 and q is 0.
- z in Formula VI is 0, R 13 , R 14 , R 15 , R 16 , or R 17 is O, and all of the bonds between adjacent R 12 to R 17 are single.
- z in Formula VI is 0, R 13 is O, and all of the bonds between adjacent R 12 to R 17 are single.
- z in Formula VI is 0, R 13 is O, all of the bonds between adjacent R 12 to R 17 are single, X b is oxygen, p is 1, q is 0 and each R 19 is hydrogen.
- R 13 and R 17 of Formula VI are O and all of the bonds between adjacent R 12 to R 17 are single.
- R 13 and R 17 of Formula VI are 0, the bonds between R 12 and R 13 , and between R 15 and R 16 are double bonds, and the rest of the bonds in the ring are single bonds.
- z in Formula VI is 1, R d is alkoxy and is bonded to R 13 , R 14 , R 15 , R 15 , R 16 , or R 17 , three of the bonds between adjacent R 12 to R 17 are double and three of the bonds between adjacent R 12 to R 17 are single.
- z in Formula VI is 1, R d is alkoxy and is bonded to R 13 , three of the bonds between adjacent R 12 to R 17 are double and three of the bonds between adjacent R 12 to R 17 are single.
- z in Formula VI is 1, R d is methoxy, and is bonded to R 13 , R 12 to R 17 are carbon atoms, three of the bonds between adjacent R 12 to R 17 are double and three of the bonds between adjacent R 12 to R 17 are single, X b is absent, p is 0 and q is 0.
- z in Formula VI is 1, R d is hydroxyl.
- z in Formula VI is 1 and R d is hydroxyl bonded at the position para- to the methylene group.
- R d is Formula III shown below:
- R 4 is a substituted alkyl and R 5 is a dialkylamino, or R 4 is a dialkylamino and R 5 is a substituted alkyl, wherein the substituted alkyl is hydroxymethyl and the dialkylamino is N,N-diethylamino.
- R d is Formula III, wherein R 4 is hydrogen and R 5 is Formula VI shown below:
- R 4 is Formula VI and R 5 is hydrogen.
- z in Formula VI is 0, R 13 , R 14 , R 15 , R 16 , or R 17 is O, and all of the bonds between adjacent R 12 to R 17 are single.
- z in Formula VI is 0, R 13 is O, and all of the bonds between adjacent R 12 to R 17 are single.
- z in Formula VI is 0, R 13 is O, all of the bonds between adjacent R 12 to R 17 are single, X b is oxygen, p is 1, q is 0 and each R 19 is hydrogen.
- z in Formula VI is 1, R d is Formula III, wherein R 4 is hydrogen and R 5 is Formula IV or Formula V shown below:
- R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are, independently, hydrogen, U 1 , U 1 +Q 1 , U 1 +Q 2 , U 1 +Q 3 , U 1 +Q 1 +Q 2 , U 1 +Q 1 +Q 3 , U 1 +Q 2 +Q 3 , or U 1 +Q 1 +Q 2 +Q 3 (preferably, in these embodiments, U 1 +Q 1 );
- R 6 , R 9 , R 10 , and R 11 are independently present or absent according to valency, and wherein the ring bonds are double or single according to valency.
- R 6 of Formula IV is alkyl. In some embodiments, R 6 is methyl.
- R 6 of Formula IV is methyl, R 7 and R 8 are hydrogen.
- z in Formula VI is 1 and R d is hydroxyl bonded at the position para- to the methylene group.
- k is 1 and R c is hydroxyl.
- k is 1, R c is hydroxyl, and X d is absent.
- k is 1, R c is hydroxyl, X d is absent, and R 21 —R 28 are hydrogen.
- R c is alkoxy
- R c is methoxy and X d is O.
- R c is methoxy
- X d is O
- R 21 —R 28 are hydrogen.
- k is 2 and R c is alkylamino.
- k is 2
- R c is methylamino
- X d is absent.
- k is 2
- R c is methylamino
- X d is absent
- R 21 —R 28 are hydrogen.
- k is 3
- X d is O
- R c is Formula III shown below:
- R 4 and R 5 are alkyl
- k is 3
- X d is O
- R c is Formula III, wherein R 4 and R 5 are methyl.
- k is 3, X d is O and R c is Formula III, wherein R 4 is hydrogen, and R 5 is carbonyl, or R 4 is carbonyl, and R 5 is hydrogen.
- k is 3, X d is O and R c is Formula III, wherein R 4 is hydrogen, and R 5 is acetyl, or R 4 is acetyl, and R 5 is hydrogen.
- k is 3 and R c is Formula III, R 4 is hydrogen, and R 5 is Formula VI shown below:
- R 4 is hydrogen and R 5 is Formula VI.
- k is 3 and R c is Formula III, wherein R 4 is hydrogen, and R 5 is Formula VI, or R 4 is hydrogen and R 5 is Formula VI, wherein z in Formula VI is 2, R 12 is N, R 13 , R 14 , R 15 , R 16 , or R 17 is S, both R d are oxo and are bonded to the S, and all of the bonds between adjacent R 12 to R 17 are single.
- k is 3 and R c is Formula III, wherein R 4 is hydrogen, and R 5 is Formula VI, or R 4 is hydrogen and R 5 is Formula VI, wherein z in Formula VI is 2, both R d are oxo and are bonded to R 15 , R 12 is N, R 15 is S, and all of the bonds between adjacent R 12 to R 17 are single.
- k is 3 and R c is Formula III, wherein R 4 is hydrogen, and R 5 is Formula VI, or R 4 is hydrogen and R 5 is Formula VI, wherein z in Formula VI is 2, both R d are oxo and are bonded to R 15 , R 12 is N, R 15 is S, and all of the bonds between adjacent R 12 to R 17 are single, X b is absent, q is 0, p is 1, and each R 19 is hydrogen.
- k is 3 and R c is Formula III, wherein R 4 is hydrogen, and R 5 is Formula VI, or R 4 is hydrogen and R 5 is Formula VI, wherein z in Formula VI is 1, R d is amino, and three of the bonds between adjacent R 12 to R 17 are double and three of the bonds between adjacent R 12 to R 17 are single.
- k is 3 and R c is Formula III, wherein R 4 is hydrogen, and R 5 is Formula VI, or R 4 is hydrogen and R 5 is Formula VI, wherein z in Formula VI is 1, R d is amino and is bonded to R 15 , and three of the bonds between adjacent R 12 to R 17 are double and three of the bonds between adjacent R 12 to R 17 are single.
- k is 3 and R c is Formula III, wherein R 4 is hydrogen, and R 5 is Formula VI, or R 4 is hydrogen and R 5 is Formula VI, wherein z in Formula VI is 1, R d is amino and is bonded to R 15 , and three of the bonds between adjacent R 12 to R 17 are double and three of the bonds between adjacent R 12 to R 17 are single, X b is absent, p is 0 and q is 0.
- k is 3 and R c is Formula III, wherein R 4 is hydrogen, and R 5 is Formula VI, or R 4 is hydrogen and R 5 is Formula VI, wherein z in Formula VI is 0, R 13 , R 14 , R 15 , R 16 , or R 17 is O, and all of the bonds between adjacent R 12 to R 17 are single.
- k is 3 and R c is Formula III, wherein R 4 is hydrogen, and R 5 is Formula VI, or R 4 is hydrogen and R 5 is Formula VI, wherein z in Formula VI is 0, R 13 is O, and all of the bonds between adjacent R 12 to R 17 are single.
- k is 3 and R c is Formula III, wherein R 4 is hydrogen, and R 5 is Formula VI, or R 4 is hydrogen and R 5 is Formula VI, wherein z in Formula VI is 0, R 13 is O, all of the bonds between adjacent R 12 to R 17 are single, X b is oxygen, p is 1, q is 0 and each R 19 is hydrogen.
- k is 3 and R c is Formula III, wherein R 4 is hydrogen, and R 5 is Formula VI, or R 4 is hydrogen and R 5 is Formula VI, wherein z in Formula VI is 1, R d is alkoxy and is bonded to R 13 , R 14 , R 15 , R 15 , R 16 , or R 17 , three of the bonds between adjacent R 12 to R 17 are double and three of the bonds between adjacent R 12 to R 17 are single.
- k is 3 and R c is Formula III, wherein R 4 is hydrogen, and R 5 is Formula VI, or R 4 is hydrogen and R 5 is Formula VI, wherein z in Formula VI is 1, R d is alkoxy and is bonded to R 13 , three of the bonds between adjacent R 12 to R 17 are double and three of the bonds between adjacent R 12 to R 17 are single.
- k is 3 and R c is Formula III, wherein R 4 is hydrogen, and R 5 is Formula VI, or R 4 is hydrogen and R 5 is Formula VI, wherein z in Formula VI is 1, R d is alkoxy such as methoxy, and is bonded to R 13 , R 12 to R 17 are carbon atoms, three of the bonds between adjacent R 12 to R 17 are double and three of the bonds between adjacent R 12 to R 17 are single, X b is absent, p is 0 and q is 0.
- w in Formula IX is 0, R 13 , R 14 , R 15 , R 15 , or R 16 is O, and, as valency permits, two of the bonds between adjacent R 12 to R 16 are double bonds, and three of the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 is O, R 12 , R 14 , R 15 and R 16 are C, the bonds between R 12 and R 16 , and between R 14 and R 15 , are double bonds, and the rest of the bonds in the ring are single bonds.
- w in Formula IX is 0, R 13 is O, R 12 , R 14 , R 15 and R 16 are C, the bonds between R 12 and R 16 , and between R 14 and R 15 , are double bonds, the rest of the bonds in the ring are single bonds, X b is absent, p is 1, q is 0, and each R 19 is hydrogen.
- w in Formula IX is 0, R 13 , R 14 , R 15 , or R 16 is O, and, the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 is O, R 12 , R 14 , R 15 and R 16 are C, and the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 is O, R 12 , R 14 , R 15 and R 16 are C, the bonds between adjacent R 12 to R 16 are single bonds, X b is absent, p is 1, q is 0, and each R 19 is hydrogen.
- w in Formula IX is 0, R 13 and R 16 are O, and the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 and R 16 are O, R 12 , R 14 and R 15 are C, the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 and R 16 are O, R 12 , R 14 and R 15 are C, the bonds between adjacent R 12 to R 16 are single bonds, X b is absent, p is 1, q is 0, and each R 19 is hydrogen.
- w in Formula IX is 0, R 13 , R 14 , R 15 , R 15 , or R 16 is N, and, as valency permits, two of the bonds between adjacent R 12 to R 16 are double bonds, and three of the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 is N, R 12 , R 14 , R 15 and R 16 are C, the bonds between R 12 and R 16 , and between R 14 and R 15 , are double bonds, and the rest of the bonds in the ring are single bonds.
- w in Formula IX is 0, R 13 is N, R 12 , R 14 , R 15 and R 16 are C, the bonds between R 12 and R 16 , and between R 14 and R 15 , are double bonds, the rest of the bonds in the ring are single bonds, X b is absent, p is 1, q is 0, and each R 19 is hydrogen.
- w in Formula IX is 0, R 13 , R 14 , R 15 , or R 16 is N, and, the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 is N, R 12 , R 14 , R 15 and R 16 are C, and the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 is N, R 12 , R 14 , R 15 and R 16 are C, the bonds between adjacent R 12 to R 16 are single bonds, X b is absent, p is 1, q is 0, and each R 19 is hydrogen.
- w in Formula IX is 0, R 13 and R 16 are N, and the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 and R 16 are N, R 12 , R 14 and R 15 are C, the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 and R 16 are N, R 12 , R 14 and R 15 are C, the bonds between adjacent R 12 to R 16 are single bonds, X b is absent, p is 1, q is 0, and each R 19 is hydrogen.
- w in Formula IX is 0, R 13 , R 14 , R 15 , R 15 , or R 16 is S, and, as valency permits, two of the bonds between adjacent R 12 to R 16 are double bonds, and three of the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 is S, R 12 , R 14 , R 15 and R 16 are C, the bonds between R 12 and R 16 , and between R 14 and R 15 , are double bonds, and the rest of the bonds in the ring are single bonds.
- w in Formula IX is 0, R 13 is S, R 12 , R 14 , R 15 and R 16 are C, the bonds between R 12 and R 16 , and between R 14 and R 15 , are double bonds, the rest of the bonds in the ring are single bonds, X b is absent, p is 1, q is 0, and each R 19 is hydrogen.
- w in Formula IX is 0, R 13 , R 14 , R 15 , or R 16 is S, and, the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 is S, R 12 , R 14 , R 15 and R 16 are C, and the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 is S, R 12 , R 14 , R 15 and R 16 are C, the bonds between adjacent R 12 to R 16 are single bonds, X b is absent, p is 1, q is 0, and each R 19 is hydrogen.
- w in Formula IX is 0, R 13 and R 16 are S, and the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 and R 16 are S, R 12 , R 14 and R 15 are C, the bonds between adjacent R 12 to R 16 are single bonds.
- w in Formula IX is 0, R 13 and R 16 are S, R 12 , R 14 and R 15 are C, the bonds between adjacent R 12 to R 16 are single bonds, X b is absent, p is 1, q is 0, and each R 19 is hydrogen.
- R 29 of Formula X is Si, and X g is alkynyl.
- R 29 of Formula X is Si, X g is ethynyl, and R 30 is alkylene.
- R 29 of Formula X is Si
- X g is ethynyl
- R 30 is methylene
- R 31 , R 32 , and R 33 are alkyl.
- R 29 of Formula X is Si
- X g is ethynyl
- R 30 is methylene
- R 31 , R 32 , and R 33 are methyl.
- Products can be either singularly modified or multiply modified.
- Singularly modified product s are products that contain one or more covalent modifications, wherein substantially all of the covalently modified products possess the same covalent modification (i.e. the product contains one ‘type’ or species of covalent modification).
- Multiply modified products are products that contain covalent modifications, wherein substantially all of the covalently modified products do not possess the same covalent modification (i.e. the product contains two or more ‘types’ or species of covalent modifications).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Ceramic Engineering (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/341,118 US20190046690A9 (en) | 2015-11-01 | 2016-11-02 | Materials with improved properties |
| US15/588,460 US20170246347A1 (en) | 2015-11-01 | 2017-05-05 | Materials with improved properties |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562249323P | 2015-11-01 | 2015-11-01 | |
| PCT/US2016/059966 WO2017075630A1 (en) | 2015-11-01 | 2016-11-01 | Materials with improved properties |
| US15/341,118 US20190046690A9 (en) | 2015-11-01 | 2016-11-02 | Materials with improved properties |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2016/059966 Continuation WO2017075630A1 (en) | 2015-11-01 | 2016-11-01 | Materials with improved properties |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/588,460 Continuation US20170246347A1 (en) | 2015-11-01 | 2017-05-05 | Materials with improved properties |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20180117216A1 US20180117216A1 (en) | 2018-05-03 |
| US20190046690A9 true US20190046690A9 (en) | 2019-02-14 |
Family
ID=57610364
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/341,118 Pending US20190046690A9 (en) | 2015-11-01 | 2016-11-02 | Materials with improved properties |
| US15/588,460 Abandoned US20170246347A1 (en) | 2015-11-01 | 2017-05-05 | Materials with improved properties |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/588,460 Abandoned US20170246347A1 (en) | 2015-11-01 | 2017-05-05 | Materials with improved properties |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190046690A9 (zh) |
| EP (1) | EP3368596A1 (zh) |
| JP (2) | JP6840751B2 (zh) |
| KR (1) | KR102558416B1 (zh) |
| CN (1) | CN108473704B (zh) |
| AU (1) | AU2016344041B2 (zh) |
| CA (1) | CA3003738C (zh) |
| IL (1) | IL258766B (zh) |
| SG (1) | SG11201803340VA (zh) |
| WO (1) | WO2017075630A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10947140B2 (en) * | 2018-04-09 | 2021-03-16 | Craig Technical Consulting, Inc. | Method for establishing a wastewater bioreactor environment |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190020318A (ko) | 2016-06-13 | 2019-02-28 | 메사추세츠 인스티튜트 오브 테크놀로지 | 이물질 반응 및 섬유화를 감소시키기 위한 생체적합성 코팅 및 하이드로겔 |
| CN111372612A (zh) | 2017-09-27 | 2020-07-03 | 西吉隆医疗股份有限公司 | 包含活性细胞的方法、组合物和可植入元件 |
| US11318231B2 (en) | 2017-11-06 | 2022-05-03 | Massachusetts Institute Of Technology | Anti-inflammatory coatings to improve biocompatibility of neurological implants |
| WO2019169245A1 (en) | 2018-03-02 | 2019-09-06 | Sigilon Therapeutics, Inc. | Biocompatible hydrogel capsules and process for preparing same |
| US20210060205A1 (en) | 2018-03-02 | 2021-03-04 | Sigilon Therapeutics, Inc. | Afibrotic compounds, devices, and uses thereof |
| US20210145889A1 (en) | 2018-04-04 | 2021-05-20 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
| TW202014181A (zh) | 2018-04-04 | 2020-04-16 | 美商希吉隆醫療公司 | 可植入顆粒及相關方法 |
| UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
| US20220089537A1 (en) | 2020-09-18 | 2022-03-24 | Massachusetts Institute Of Technology | High-throughput method to rapidly add chemical moieties to a small molecule library |
| CN112335623A (zh) * | 2020-11-09 | 2021-02-09 | 陈金刚 | 一种基于病虫害防治技术的害虫诱杀装置 |
| CN114958793B (zh) * | 2022-05-31 | 2024-02-02 | 深圳大学 | 一种制备高催化活性mNampt突变体的方法及其突变体、重组菌以及应用 |
| WO2023235884A1 (en) | 2022-06-03 | 2023-12-07 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods |
| WO2024006528A1 (en) | 2022-07-01 | 2024-01-04 | Sigilon Therapeutics, Inc. | Covalently photocrosslinked polysaccharides and methods of use thereof |
| WO2024081310A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
| WO2024081309A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6171232B1 (en) * | 1997-06-26 | 2001-01-09 | Cordis Corporation | Method for targeting in vivo nitric oxide release |
| US6159531A (en) * | 1999-08-30 | 2000-12-12 | Cardiovasc, Inc. | Coating having biological activity and medical implant having surface carrying the same and method |
| US6977138B2 (en) * | 2001-07-24 | 2005-12-20 | Massachusetts Institute Of Technology | Reactive polymer coatings |
| DE102005008434A1 (de) | 2005-02-24 | 2006-09-07 | Forschungszentrum Jülich GmbH | Verfahren zur Modifizierung eines Substrats |
| US20080003250A1 (en) | 2006-06-21 | 2008-01-03 | Margulies Barry J | Novel therapy for herpesvirus infection |
| US8211361B2 (en) * | 2007-03-26 | 2012-07-03 | Board Of Regents, The University Of Texas System | N-halamine-based rechargeable biofilm-controlling tubular devices, method of making and using |
| US7998524B2 (en) * | 2007-12-10 | 2011-08-16 | Abbott Cardiovascular Systems Inc. | Methods to improve adhesion of polymer coatings over stents |
| EP2127689A1 (en) | 2008-05-27 | 2009-12-02 | RevisiOs B.V. i.o. | Novel homogenous osteoinductive nanocomposites |
| ES2476140T3 (es) * | 2009-02-09 | 2014-07-11 | St. Jude Medical, Inc. | Mejora de la biocompatibilidad de un dispositivo m�dico |
| US9555154B2 (en) | 2009-02-21 | 2017-01-31 | Covidien Lp | Medical devices having activated surfaces |
| ES2725549T3 (es) | 2010-07-12 | 2019-09-24 | Univ Southern California | Sustrato biocompatible para facilitar las interconexiones entre células madre y tejidos diana y métodos para implantarlo |
| EP3354665B9 (en) | 2011-06-02 | 2022-08-03 | Massachusetts Institute of Technology | Modified alginates for cell encapsulation and cell therapy |
| WO2013086419A1 (en) * | 2011-12-09 | 2013-06-13 | California Institute Of Technology | Polymer scaffolds and their use in the treatment of vision loss |
| US10426735B2 (en) * | 2014-08-01 | 2019-10-01 | Massachusetts Institute Of Technology | Modified alginates for anti-fibrotic materials and applications |
| DK3368085T3 (da) | 2015-11-01 | 2024-04-02 | Massachusetts Inst Technology | Modificerede alginater til anti-fibrotiske materialer og anvendelser |
-
2016
- 2016-11-01 CN CN201680076377.2A patent/CN108473704B/zh active Active
- 2016-11-01 CA CA3003738A patent/CA3003738C/en active Active
- 2016-11-01 JP JP2018521862A patent/JP6840751B2/ja active Active
- 2016-11-01 AU AU2016344041A patent/AU2016344041B2/en active Active
- 2016-11-01 EP EP16816769.0A patent/EP3368596A1/en active Pending
- 2016-11-01 SG SG11201803340VA patent/SG11201803340VA/en unknown
- 2016-11-01 KR KR1020187015643A patent/KR102558416B1/ko active IP Right Grant
- 2016-11-01 WO PCT/US2016/059966 patent/WO2017075630A1/en active Application Filing
- 2016-11-02 US US15/341,118 patent/US20190046690A9/en active Pending
-
2017
- 2017-05-05 US US15/588,460 patent/US20170246347A1/en not_active Abandoned
-
2018
- 2018-04-17 IL IL258766A patent/IL258766B/en active IP Right Grant
-
2020
- 2020-11-17 JP JP2020190827A patent/JP7107533B2/ja active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10947140B2 (en) * | 2018-04-09 | 2021-03-16 | Craig Technical Consulting, Inc. | Method for establishing a wastewater bioreactor environment |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7107533B2 (ja) | 2022-07-27 |
| US20180117216A1 (en) | 2018-05-03 |
| CA3003738A1 (en) | 2017-05-04 |
| CN108473704B (zh) | 2021-09-28 |
| JP2021028334A (ja) | 2021-02-25 |
| JP6840751B2 (ja) | 2021-03-10 |
| AU2016344041A1 (en) | 2018-06-14 |
| KR102558416B1 (ko) | 2023-07-24 |
| AU2016344041B2 (en) | 2019-11-07 |
| IL258766B (en) | 2021-05-31 |
| KR20180107080A (ko) | 2018-10-01 |
| SG11201803340VA (en) | 2018-05-30 |
| JP2018535966A (ja) | 2018-12-06 |
| IL258766A (en) | 2018-06-28 |
| EP3368596A1 (en) | 2018-09-05 |
| CN108473704A (zh) | 2018-08-31 |
| CA3003738C (en) | 2021-01-12 |
| WO2017075630A1 (en) | 2017-05-04 |
| US20170246347A1 (en) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016344041B2 (en) | Materials with improved properties | |
| US20220031913A1 (en) | Modified alginates for anti-fibrotic materials and applications | |
| US11266606B2 (en) | Modified alginates for anti-fibrotic materials and applications | |
| US10730983B2 (en) | Biocompatible coatings and hydrogels for reducing foreign body response and fibrosis | |
| Ashammakhi et al. | Highlights on advancing frontiers in tissue engineering | |
| La Flamme et al. | Biocompatibility of nanoporous alumina membranes for immunoisolation | |
| JP2019531695A (ja) | 人工組織前駆体及びそれを調製する方法 | |
| JP2004337176A (ja) | 中枢神経系への遺伝子導入のための方法 | |
| Datta et al. | Role of tissue engineering in organ regeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VEISEH, OMID;LANGER, ROBERT S.;ANDERSON, DANIEL G.;SIGNING DATES FROM 20161108 TO 20170504;REEL/FRAME:042257/0559 Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VEGAS, ARTURO J.;DOLOFF, JOSHUA C.;SIGNING DATES FROM 20161108 TO 20170505;REEL/FRAME:042257/0565 Owner name: THE CHILDREN'S MEDICAL CENTER CORPORATION, MASSACH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VEGAS, ARTURO J.;DOLOFF, JOSHUA C.;SIGNING DATES FROM 20161108 TO 20170505;REEL/FRAME:042257/0565 |
|
| AS | Assignment |
Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VEISEH, OMID;LANGER, ROBERT S.;ANDERSON, DANIEL G.;SIGNING DATES FROM 20161108 TO 20170504;REEL/FRAME:042853/0270 Owner name: THE CHILDREN'S MEDICAL CENTER CORPORATION, MASSACH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VEGAS, ARTURO J.;DOLOFF, JOSHUA C.;SIGNING DATES FROM 20161108 TO 20170505;REEL/FRAME:042853/0210 Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VEGAS, ARTURO J.;DOLOFF, JOSHUA C.;SIGNING DATES FROM 20161108 TO 20170505;REEL/FRAME:042853/0210 Owner name: US ARMY, SECRETARY OF THE ARMY, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:MASSACHUSETTS INSTITUTE OF TECHNOLOGY;REEL/FRAME:043026/0909 Effective date: 20170123 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
| STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |